bioc-10q_20160930.htm

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 4, 2016, there were 17,499,397 shares of the Registrant’s common stock outstanding.

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included or incorporated by reference in this Quarterly Report other than statements of historical fact, are forward-looking statements. You can identify these and other forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements speak only as of the date on which they are made and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made except as required by law. Readers should, however, review the factors and risks we describe in the reports and registration statements we file from time to time with the SEC.

The accompanying notes are an integral part of these unaudited condensed financial statements.

A public offering of the Company’s common stock and warrants to purchase its common stock was effected on February 9, 2015, the closing of which occurred on February 13, 2015 (see Note 3). In connection with the closing of this offering, (i) warrants were issued to buy (in the aggregate) up to 2,666,666 shares of common stock at an exercise price of $4.68 per share with a term of five years and an estimated grant date fair value of approximately $7.7 million, which was recorded as an offset to additional paid-in capital within common stock issuance costs, (ii) the underwriters were granted a 45 day option from the closing date of this offering to purchase up to 400,000 additional shares of common stock at a price of $3.75 per share and/or additional warrants to purchase up to 400,000 shares of common stock at a price of $0.0003 per warrant, less underwriting discounts and commissions, to cover overallotments, if any, with an aggregate estimated grant date fair value of approximately $1.6 million that was recorded to common stock issuance costs, and (iii)

costs of $63,111 directly associated with this offering that were included in prepaid expenses and other current assets at December 31, 2014 were reclassified to common stock issuance costs.

A public offering of the Company’s common stock and warrants to purchase its common stock was effected on April 29, 2016, the closing of which occurred on May 4, 2016 (see Note 3). In connection with the closing of this offering, warrants were issued to buy (in the aggregate) up to 1,163,526 shares of common stock at an exercise price of $3.90 per share with a term of five years and an estimated grant date fair value of approximately $2.0 million, which was recorded as an offset to additional paid-in capital within common stock issuance costs (see Note 4).

Fixed assets purchased totaling $279,008 and $631,232 during the nine months ended September 30, 2015 and 2016, respectively, were recorded as equipment financing obligations and were excluded from cash purchases in the Company’s unaudited condensed statements of cash flows. During the nine months ended September 30, 2016, a financing agreement underlying a fixed asset with a remaining net book value of $126,811, which was previously recorded as an equipment financing obligation, was cancelled.

The amount of unpaid fixed asset purchases excluded from cash purchases in the Company’s unaudited condensed statements of cash flows decreased from $19,546 at December 31, 2014 to $3,190 at September 30, 2015. The amount of unpaid fixed asset purchases excluded from cash purchases in the Company’s unaudited condensed statements of cash flows decreased from $64,300 at December 31, 2015 to $8,637 at September 30, 2016.

During the nine months ended September 30, 2016, the Company financed insurance premiums of $434,475 through third party financings.

A public offering of the Company’s common stock and warrants to purchase its common stock was effected on October 14, 2016, the closing of which occurred on October 19, 2016 (see Note 13). In connection with the closing of this offering, warrants to purchase up to an aggregate of 9,100,000 shares of common stock with estimated grant date fair value of approximately $0.57 per share were issued, and a corresponding total of approximately $5.2 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. Additionally, the underwriters were granted a 30-day option to purchase up to 1,365,000 additional shares of common stock at a price of $1.0331 per share, net of the underwriting discount, and/or additional warrants to purchase up to 1,365,000 shares of common stock at a price of $0.0009 per warrant to cover overallotments, if any. Through the date that these unaudited condensed financial statements were available to be issued, the underwriters have exercised their overallotment option to purchase 627,131 option warrants for total proceeds to the Company of $564. The estimated aggregate grant date fair value of the overallotment options and warrants of approximately $0.8 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $1.10, are exercisable immediately and expire five years from the date of issuance. As of September 30, 2016, a total of $130,252 of costs directly associated with this offering were accrued and recorded in prepaid expenses and other current assets, of which none were paid as of September 30, 2016 and thus excluded from changes in both prepaid expenses and other current assets and accounts payable in the Company’s unaudited condensed statement of cash flows, and which were also subsequently reclassified to common stock issuance costs as an offset to additional paid in capital upon the closing of this offering.

The accompanying notes are an integral part of these unaudited condensed financial statements.

The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.

The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock, which was not affected by the one-for-three reverse stock split.

Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor.

The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.

In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.

In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim

reporting period ended September 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.

In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

As of September 30, 2016, cash and cash equivalents totaled $0.7 million and the Company had an accumulated deficit of $169.4 million. For the year and nine month periods ended December 31, 2015 and September 30, 2016, the Company incurred net losses of $16.9 million and $14.2 million, respectively. At September 30, 2016, the Company had aggregate gross interest-bearing indebtedness of approximately $5.3 million, of which approximately $2.2 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to approximately $2.8 million of other non-interest bearing liabilities. Additionally, in February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly installments of $62,500 through May 2020 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations.

Subsequent to the closing of a follow-on public offering on February 13, 2015, cash proceeds of approximately $9.8 million have been received by the Company from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $4.68 per share until their expiration in February 2020. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.3 million (see Note 3). Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million (see Note 13).

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis Capital Corp. and Feltl and Company, Inc., as underwriters named therein, a public offering of 2,666,666 shares of the Company’s common stock and warrants to purchase up to an aggregate of 2,666,666 shares of common stock was effected at a combined offering price of $3.75. The estimated grant date

fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $4.68, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on February 13, 2015, when the Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $9.1 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was $8.8 million after deducting $0.3 million of additional non-underwriter costs incurred. Additionally, the underwriters were granted a 45-day option to purchase up to 400,000 additional shares of common stock at a price of $3.75 per share and/or additional warrants to purchase up to 400,000 shares of common stock at a price of $0.0003 per warrant, less underwriting discounts and commissions, to cover overallotments, if any, which was not exercised. The estimated grant date fair value of the overallotment options and warrants of $1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. Underwriter costs and discounts of $0.2 million and $0.7 million, respectively, as well as additional non-underwriter costs associated with this offering of $0.3 million, were also recorded to common stock issuance costs upon closing. Subsequent to the closing of this offering on February 13, 2015, additional cash proceeds of $9.8 million have been received from the exercise of warrants sold in such offering. As such, the aggregate total increase in capital related to this offering has been $18.6 million, after deducting the $0.9 million of underwriter costs and discounts and $0.3 million of additional non-underwriter costs incurred, which were offset against these proceeds under applicable accounting guidance.

In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 1,662,191 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to Roth Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.3 million after deducting an estimated $0.3 million of additional third party costs incurred in connection with this offering. An aggregate balance of approximately $0.7 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. On November 4, 2016, the Company voluntarily terminated this common stock purchase agreement (see Note 13). Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 208,334 shares of common stock at $4.80 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that were issued to Aspire Capital under the common stock purchase agreement. Under the common stock purchase agreement, on any trading day selected by the Company, the Company had the right, in its sole discretion, to present a purchase notice directing Aspire Capital to purchase up to 33,333 shares of the Company’s common stock per business day, up to $15.0 million of common stock in the aggregate at a per share price equal to the lesser of either (i) the lowest sale price of the Company’s common stock on the purchase date, or (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which the Company submitted a purchase notice to Aspire Capital in an amount equal to 33,333 shares and the Company’s stock price was not less than $1.50 per share, the Company also had the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on the its principal market on the next trading day, subject to a maximum number of shares the Company could determine. The purchase price per share pursuant to such volume-weighted average price purchase notice was generally 97% of the volume-weighted average price for the Company’s common stock traded on its principal market on the volume-weighted average purchase date. The purchase price was to be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the

purchase price. The Company could have delivered multiple purchase notices and volume-weighted average price purchase notices to Aspire Capital from time to time during the term of the common stock purchase agreement, so long as the most recent purchase had been completed. The common stock purchase agreement provided that the Company and Aspire Capital would not effect any sales on any purchase date where the closing sale price of the Company’s common stock was less than $1.50. There were no trading volume requirements or restrictions under the common stock purchase agreement, and the Company controlled the timing and amount of sales of its common stock to Aspire Capital. Aspire Capital had no right to require any sales by the Company, but was obligated to make purchases from the Company as directed by the Company in accordance with the common stock purchase agreement. There were no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 55,000 shares of its common stock. The common stock purchase agreement could have been terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital had agreed that neither it nor any of its agents, representatives and affiliates were to engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the common stock purchase agreement. The proceeds received by the Company under the common stock purchase agreement were used for working capital and general corporate purposes. During the nine months ended September 30, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 173,145 shares of common stock for gross proceeds of $544,051. Costs associated with this offering of approximately $42,000 and $83,000 during the year ended December 31, 2015 and nine months ended September 30, 2016, respectively, were also recorded to common stock issuance costs under applicable accounting guidance, and as such, the aggregate total increase in capital related to this transaction was approximately $1.4 million.

The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.

As of the closing of the Company’s public offering in May 2016, the estimated grant date fair value of $1.72 per share associated with the warrants to purchase 1,163,526 shares of common stock issued in such offering, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions:

The estimated fair value of the April 2014 Credit Facility at September 30, 2016 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid.

On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment required the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final payment of $50,000 to the lender. If on or before September 30, 2016 the Company received unrestricted net cash proceeds of at least $7.0 million from the issuance and sale its equity securities, or the Company received a signed letter of intent relating to a sale or merger of the Company, in form and substance satisfactory to the lender, the Company could have been required to make interest-only payments on the term loan through December 31, 2016, and the amount of the additional final payment to the lender upon repayment would have increased to $75,000, which did not occur. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the Company’s 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance.

The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among

others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000.

A warrant to purchase up to 17,655 shares of the Company’s common stock at an exercise price of $14.16 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The effective annual interest rate associated with the April 2014 Credit Facility was 11.50% and 13.87% at December 31, 2015 and September 30, 2016, respectively.

The Company leases certain laboratory equipment under arrangements classified as capital leases. The leased equipment is depreciated on a straight-line basis over periods ranging from 5 to 7 years. Total gross value of fixed assets capitalized under such lease arrangements was $914,179 and $1,457,377 at December 31, 2015 and September 30, 2016, respectively. Total accumulated depreciation related to the leased equipment was approximately $523,000 and $616,000 at December 31, 2015 and September 30, 2016, respectively. Total depreciation expense for the leased equipment was approximately $24,000 and $40,000 for the three months ended September 30, 2015 and 2016, respectively, and was approximately $49,000 and $93,000 for the nine months ended September 30, 2015 and 2016, respectively. The weighted average effective annual interest rates related to the lease obligations are 13.35% and the maturity dates on outstanding arrangements range from July 2017 to May 2023.

The following schedule sets forth the future minimum lease payments, as well as corresponding laboratory equipment maintenance obligations that are not recorded as part of the leased equipment balances within fixed assets or capital lease obligations, outstanding under capital leases and due within each respective year ending December 31, and the present value of the minimum lease payments as of September 30, 2016:

At September 30, 2016, the present value of minimum lease payments due within one year was $255,605.

On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The following per share amounts and share numbers have been adjusted for this reverse stock split as if it had occurred on January 1, 2015.

period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. In conjunction with the one-for-three reverse split of the Company’s common stock effected on September 27, 2016, the number of non-inducement shares authorized under all plans decreased from 3,068,865 to 1,022,955 shares, and the number of inducement shares authorized under the 2013 Plan decreased from 1,000,000 shares to 333,333 shares. As of September 30, 2016, under all plans, a total of 1,022,955 non-inducement shares were authorized for issuance, 978,358 non-inducement stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 3,115 non-inducement shares were available for grant. As of September 30, 2016, a total of 333,333 inducement shares were authorized for issuance, 124,999 inducement stock options and RSUs had been issued and were outstanding, and 208,334 inducement shares were available for grant under the 2013 Plan.

A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

The intrinsic values of options outstanding and options vested and unvested expected to vest at September 30, 2016 were both zero. The intrinsic value of options exercisable at September 30, 2016 was zero.

The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:

Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the nine months ended September 30, 2016 was $1.86 per share.

On August 31, 2015, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $4.40 per share to its Chief Executive Officer pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $2.87 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:

On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, on July 29, 2016 the CFO was granted inducement stock option awards to purchase up to (i) 66,666 shares of the Company’s common stock with an estimated grant date fair value of $1.45 per share, 25% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which will vest in equal monthly installments over the following three years, and (ii) 33,333 shares of the Company’s common stock with an estimated grant date fair value of $1.26 per share, which vest upon the Company’s achievement of specified corporate goals for 2016 and the consummation of a specified financing transaction.

A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

The RSUs granted during the nine months ended September 30, 2016 vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. At September 30, 2016, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $277,496 and $270,904, respectively.

On June 12, 2014, the Company’s Board of Directors granted an RSU award for 14,832 shares with a grant date fair value of $16.05 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:

During the nine months ended September 30, 2016, a total of 4,449 RSUs were declared vested by the Company’s Board of Directors and issued to its Chief Executive Officer in satisfaction of this award and the remaining 10,383 shares underlying this RSU were forfeited.

On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 58,332 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 25,000 shares of common stock to its Chief Executive Officer. Each of these retention RSUs has a grant date fair value of $1.86 per share for a grant date fair value of $108,498 to all three officers, in aggregate. These retention RSUs vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs.

Pursuant to the terms of the Company’s employment agreement with its CFO dated July 25, 2016, the CFO was granted an inducement RSU award on July 29, 2016 covering 25,000 shares of the Company’s common stock with a grant date fair value of $1.95 per share, 100% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company.

The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:

Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 4% and 0% - 8% per annum during the three and nine months ended September 30, 2015 and 2016, respectively. As of September 30, 2016, total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,081,000 and is expected to be recognized over a weighted-average period of 2.1 years.

On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The summary of equity-classified common stock warrant activity has been adjusted for this reverse stock split as if it had occurred on December 31, 2015.

A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2016 is as follows:

The intrinsic value of equity-classified common stock warrants outstanding and exercisable at September 30, 2016 was zero.

Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the nine months ended September 30, 2015 and 2016, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.

On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse stock split as if it had occurred on January 1, 2015.

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

In February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020.

All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 47,331 shares of the Company’s common stock and warrants to purchase up to an aggregate of 47,331 shares of its common stock for total gross proceeds of $177,500 (see Note 3).

A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of $19,047 during the nine months ended September 30, 2016 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement.

Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable

security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A total of $64,020 and $115,236 in rental income was recorded to other income in the Company’s unaudited condensed statements of operations and comprehensive loss during the nine months ended September 30, 2015 and 2016, respectively.

Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 58,335 shares of the Company’s common stock and warrants to purchase up to an aggregate of 40,832 shares of its common stock for total gross proceeds to the Company of $175,000. Additionally, a trust affiliated with the Company’s major stockholder, Claire K.T. Reiss, participated in its public offering in May 2016, purchasing 204,758 shares of its common stock and warrants to purchase up to 143,330 shares of its common stock for total gross proceeds to the Company of $614,273 (see Note 3).

The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million. The estimated grant date fair value of these warrants of approximately $0.57 per share, or a total of approximately $5.2 million, was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. Additionally, the underwriters were granted a 30-day option to purchase up to 1,365,000 additional shares of common stock at a price of $1.0331 per share, net of the underwriting discount, and/or additional warrants to purchase up to 1,365,000 shares of common stock at a price of $0.0009 per warrant to cover overallotments, if any. Through the date that these unaudited condensed financial statements were available to be issued, the underwriters have exercised their overallotment option to purchase 627,131 option warrants for total proceeds to the Company of $564. The estimated aggregate grant date fair value of the overallotment options and warrants of approximately $0.8 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $1.10, are exercisable immediately and expire five years from the date of issuance. The fair values of these overallotment options and all warrants issued in the October 2016 offering were estimated using Black-Scholes valuation models with the following assumptions:

Seven members of the Company’s Board of Directors, including its Chief Executive Officer, and all three of the Company’s other executive officers participated in the Company’s public offering in October 2016, purchasing an aggregate of 534,088 shares of common stock and warrants to purchase up to an aggregate of 534,088 shares of common stock for total gross proceeds to the Company of $587,497. Additionally, a trust affiliated with the Company’s major shareholder, Claire K.T. Reiss, participated in the Company’s public offering in October 2016, purchasing 227,272 shares of its common stock and warrants to purchase up 227,272 shares of its common stock for total gross proceeds to the Company of $249,999. Further, several of the Company’s employees and one of its consultants participated in the Company’s public offering in October 2016, purchasing an aggregate of 79,090 shares of its common stock and warrants to purchase up to an aggregate of 79,090 shares of its common stock for total aggregate gross proceeds to the Company of $86,999. The closing of the sale of these securities to the underwriters occurred on October 19, 2016, when the Company received, after deducting $0.6 million of underwriters’ discount and additional costs paid to the underwriters, $9.4 million of net cash proceeds. Subsequent to the closing of this offering on October 19, 2016 and through the date that these unaudited condensed financial statements were available to be issued, no additional cash proceeds had been received from the exercise of warrants sold in such offering. As such, the total increase in capital as a result of the sale of these shares and warrants is $8.8 million after deducting the $0.6 million of underwriter fees and costs and the estimated additional $0.6 million of non-underwriter costs incurred, which were offset against these proceeds under applicable accounting guidance.

The Company does not expect to report a provision for income taxes until it has a history of earnings, if ever, that would support the realization of its deferred tax assets.

The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, the Company believes ownership changes likely occurred in both 2015 and 2016. As a result, the Company has estimated that the use of its net operating loss is limited and the remaining net operating loss carryforwards and research and development credits it estimates can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero.

On November 4, 2016, the Company voluntarily terminated the common stock purchase agreement that the Company entered into on December 21, 2015, with Aspire Capital. Pursuant to this common stock purchase agreement, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2015 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission on March 10, 2016. Past operating results are not necessarily indicative of results that may occur in future periods. The share numbers in the following discussion reflect a one-for-three reverse common stock split that we effected on September 27, 2016.

We are an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” Our assays provide, and our planned future assays would provide, information to oncologists and other physicians that enable them to select appropriate personalized treatment for their patients who have been diagnosed with cancer based on timelier and more contemporaneous data on the characteristics of their patients’ tumors.

Our current assays and our planned future assays focus on key solid tumor indications utilizing our Target-Selector^TM CTC offering for the biomarker analysis of CTCs and ctDNA from a standard blood sample. The Target-Selector CTC offering is based on an internally developed and patented, microfluidics-based capture and analysis platform, with enabling features that change how CTC testing is used by clinicians. The Target-Selector platforms provide both biomarker detection as well as monitoring capabilities, and require only a blood sample. Our patent pending Target-Selector ctDNA technology enables mutation detection with enhanced sensitivity and specificity and is applicable to nucleic acid from CTCs or other sample types, such as blood, plasma, or cerebrospinal fluid. We believe the Target-Selector technology can someday be used as a stand-alone test for molecular biomarker screening, marked as in vitro diagnostics kits.

At our corporate headquarters facility located in San Diego, California, we operate a clinical laboratory that is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American Pathologists. We manufacture our microfluidic channels, related equipment and certain reagents to perform our current assays and our planned future assays at this facility. CLIA certification is required before any clinical laboratory, including ours, may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, or treatment of disease or the assessment of health. The assays we offer and intend to offer are classified as laboratory developed tests, or LDTs, under CLIA regulations.

We are commercializing our Target-Selector assays for a number of solid tumor indications such as: breast cancer, non-small cell lung cancer, or NSCLC, small cell lung cancer, or SCLC, gastric cancer, colorectal cancer, prostate cancer, and melanoma. These assays utilize our dual CTC and ctDNA technology platform and provide biomarker analysis from a standard blood sample.

In the case of our breast and gastric cancer offering, biomarker analysis involves fluorescence in situ hybridization, or FISH, for the detection and quantitation of the human epidermal growth factor receptor 2, or HER2, gene copy number as well as immunocytochemical analysis of estrogen receptor, or ER, protein, as well as androgen receptor, or AR, protein, which are currently commercially available. We plan to include immunocytochemical analysis of progesterone receptor, or PR, proteins as part of the Target-Selector CTC menu in 2017. A patient’s HER2 status provides the physician with information about the appropriateness of therapies such as Herceptin® or Tykerb®. ER and PR status provides the physician with information about the appropriateness of endocrine therapies such as tamoxifen and aromatase inhibitors.

The lung cancer biomarker analyses currently include FISH testing for ALK, ROS1, RET, MET and FGFR1 gene rearrangements and mutation analysis of the T790M, Deletion 19, and L858R mutations of the epidermal growth factor receptor, or EGFR, gene as well as BRAF and KRAS using our Target-Selector ctDNA platform. The L858R mutation of the EGFR gene and Exon 19 deletions as activators of EGFR kinase activity are associated with the drugs Tarceva®, Gilotrif® and Iressa®. For lung cancer, we also offer a resistance panel assay consisting of the biomarkers MET, HER2 (both of which we perform using our technology for CTCs), KRAS, and T790M (both of which are performed using ctDNA in plasma). This assay could be used by physicians to identify the mechanism causing disease progression for patients with NSCLC who are being treated with TKI therapy and therefore could qualify for inclusion in a clinical trial. In November 2015, Tagrisso® was approved by the U.S. Food and Drug Administration, providing another biomarker based therapy for the treatment of patients with EGFR related lung cancer. Tagrisso® is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR tyrosine kinase inhibitor therapy.

Fibroblast growth receptor 1, or FGFR1, amplification is offered using our CTC technology. FGFR1 is present in several tumor types, including both NSCLC and SCLC and has been shown to be a prognostic indicator of progression. FGFR1 is also a key target for many drugs which are in clinical development.

Mutations of the BRAF gene are associated with Zelboraf® and Tafinlar®, which are both approved for treating patients with melanoma and are in clinical trials for lung cancer. We offer testing for BRAF on blood using our ctDNA offering.

We recently analytically validated PD-L1 testing utilizing our CTC technology. PD-L1 is a biomarker that is informative for immuno-oncology therapies currently marketed today for lung cancer and melanoma, as well as in development for multiple tumor types. We collaborated with David Rimm, M.D., Ph.D., a pathologist at Yale Medical School, on the analytical development of this assay.

We plan to add other biomarker analyses, such as ESR1 and NRAS, on blood samples to our current assays and our planned future Target-Selector CTC assays as their relevance is demonstrated in clinical trials and/or included in guidelines used by physicians to make treatment decisions.

We continue to execute on our strategies of expanding our business globally as well as engaging with pharmaceutical companies on clinical trials and assay development. We have executed distribution agreements in Mexico with Quest Diagnostics to support testing for a large pharmaceutical partner, as well as an agreement with Progenetics to market our assays in Israel for clinical testing.

We announced three additional pharmaceutical collaborations during 2016. The first agreement is to provide testing for a clinical trial that includes patients who have leptomeningeal disease or metastatic lung cancer to the brain. In this exploratory trial, we are testing both cerebral spinal fluid and blood for molecular alterations that could be impacted by treatment. The second agreement is a large milestone-based multi-project assay development collaboration focused on hepatocellular carcinoma, or liver cancer, whereby we will develop assays utilizing both our CTC and ctDNA technologies for clinical trials. The third collaboration involves a study presented at the European Society for Medical Oncology, or ESMO, Annual Congress in October 2016, whereby collaborators from a large pharmaceutical company, as well as academic investigators, demonstrated a high concordance between our Target-Selector liquid biopsy and tissue biopsy. Subsequent to this study, we have earned business in both Mexico and Columbia for EGFR testing in blood to qualify patients for the pharmaceutical company’s targeted therapy.

The following tables set forth certain information concerning our commercial cases accessioned for the periods shown:

Revenues from commercial cases are recognized as collected, and the expected collection period for a commercial case often extends beyond the end of the quarter in which accessioned, with multiple payments received per case. For commercial accessions received during the nine months ended September 30, 2015 and 2016, the average number of tests performed increased from 2.4 tests per accession to 3.8 tests per accession, respectively. For commercial accessions received from January 1, 2016 through September 30, 2016, the expected price to be collected at 2016 Medicare schedule rates ranged from less than $200 per accession to over $5,000 per accession, and the weighted-average expected price to be collected is approximately $1,185 per accession, although such reimbursement experience has not yet been achieved. Relatively higher reimbursement rates are expected to be achieved for cases billed to certain private payors where we have agreements. Approximately 47% of the number of commercial accessions billed from January 1, 2016 through September 30, 2016 were subject to Medicare reimbursement rates, and approximately 50% and 45% of commercial revenues and total revenues, respectively, during the nine months ended September 30, 2016 were associated with Medicare reimbursement. We have not historically been reimbursed at these average rates for a variety of reasons, including billing challenges related to changes in Medicare CPT codes for our FISH assays in 2015, establishing our associated internal processes, and also managing an external “out-sourced” billing company. Additionally, a significant amount of our non-Medicare business (private payors) has historically not been contracted, and reimbursement for this business has historically not been at “in network” rates and has therefore been inconsistent. We did begin to contract private payor networks in 2015 and continue to do so in 2016, and our number of accessions treated as “in network” increased and reimbursement is improving. We are currently contracted with eight Preferred Provider Organization networks, one large health plan, and three regional Independent Physician Associations, and expect to continue to gain contracts in order to be considered as an “in-network” provider with additional plans.

The following table sets forth certain information concerning our results of operations for the periods shown:

Revenues were approximately $1,047,000 for the three months ended September 30, 2016, compared with approximately $165,000 for the same period in 2015, an increase of $882,000, or 535%. The increase was due to an increase of approximately $840,000 in commercial assay revenues resulting primarily from increases in both commercial accession volume and collections made thereon, as well as an increase of approximately $42,000 in development services revenues with 156 development services accessions received during the three months ended September 30, 2016 as compared to 88 accessions received during the same period in 2015.

Cost of Revenues. Cost of revenues was approximately $1,876,000 for the three months ended September 30, 2016, compared with approximately $1,160,000 for the three months ended September 30, 2015, an increase of $716,000, or 62%. The increase was primarily attributable to an increase of approximately $645,000 in personnel, materials, and other direct costs mainly related to higher assay volume, an increase of approximately $49,000 in third party consulting fees, as well as an increase of approximately $22,000 related to fewer laboratory costs charged to research and development.

Research and Development Expenses. Research and development expenses were approximately $601,000 for the three months ended September 30, 2016, compared with approximately $678,000 for the three months ended September 30, 2015, a decrease of $77,000, or 11%. The decrease was primarily attributable to a decrease of approximately $43,000 in materials and supplies consumed in performing research and development activities, as well as a decrease of approximately $22,000 in laboratory costs charged to research and development.

General and Administrative Expenses. General and administrative expenses were approximately $1,920,000 for the three months ended September 30, 2016, compared with approximately $1,630,000 for the three months ended September 30, 2015, an increase of $290,000, or 18%. The increase was primarily due to an increase of approximately $144,000 in consulting and other third party service provider costs mainly related to expanded commercial activities, an increase of $74,000 in third party billing fees associated with increased cash collections on commercial revenues, and an increase of approximately $60,000 in legal fees primarily associated with patents.

Sales and Marketing Expenses. Sales and marketing expenses were approximately $1,278,000 for the three months ended September 30, 2016, compared with approximately $1,056,000 for the three months ended September 30, 2015, an increase of $222,000, or 21%. The increase was due to approximately $223,000 in additional personnel costs and travel expenses associated with an increase in the average number of employees included in the sales and marketing function from 12 employees during the three months ended September 30, 2015 to 15 employees during the same period in 2016.

Over the past several years we have generated operating losses in all jurisdictions in which we may be subject to income taxes. As a result, we have accumulated significant net operating losses and other deferred tax assets. Because of our history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized. We do not expect to report a provision for income taxes until we have a history of earnings, if ever, that would support the realization of our deferred tax assets.

We have not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, we believe ownership changes likely occurred in both 2015 and 2016. As a result, we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero.

The following table sets forth certain information concerning our results of operations for the periods shown:

Revenues were approximately $1,932,000 for the nine months ended September 30, 2016, compared with approximately $392,000 for the same period in 2015, an increase of $1,540,000, or 393%. The increase was due to an increase of approximately $1,428,000 in commercial assay revenues resulting primarily from increases in both commercial accession volume and collections made thereon, as well as an increase of approximately $112,000 in development services revenues with 382 development services accessions received during the nine months ended September 30, 2016 as compared to 182 accessions received during the same period in 2015.

Cost of Revenues. Cost of revenues was approximately $5,021,000 for the nine months ended September 30, 2016, compared with approximately $3,321,000 for the nine months ended September 30, 2015, an increase of $1,700,000, or 51%. The increase was primarily attributable to an increase of approximately $1,531,000 in personnel, materials, and other direct costs mainly related to higher assay volume, an increase of approximately $78,000 related to fewer laboratory costs charged to research and development, as well as an increase of approximately $72,000 in third party consulting fees.

Research and Development Expenses. Research and development expenses were approximately $2,045,000 for the nine months ended September 30, 2016, compared with approximately $2,073,000 for the nine months ended September 30, 2015, a decrease of $28,000, or 1%. The decrease was primarily attributable to a decrease of approximately $78,000 related to fewer laboratory costs charged to research and development, a decrease of approximately $42,000 in third party consulting fees, and a decrease of approximately $21,000 in materials and supplies consumed in performing research and development activities, partially offset by an increase of approximately $120,000 related to an increase in the average number of employees included in the research and development function from 8 employees during the nine months ended September 30, 2015 to 11 employees during the same period in 2016.

General and Administrative Expenses. General and administrative expenses were approximately $4,925,000 for the nine months ended September 30, 2016, compared with approximately $4,282,000 for the nine months ended September 30, 2015, an increase of $643,000, or 15%. The increase was primarily due to an increase of approximately $204,000 in consulting and other third party service provider costs mainly related to expanded commercial activities, an increase of $156,000 in third party billing fees associated with increased cash collections on commercial revenues, an increase of approximately $114,000 related to an increase in the average number of employees included in the general and administrative function from 7 employees during the nine months ended September 30, 2015 to 9 employees during the same period in 2016, an increase of approximately $100,000 due to increased allocated facility costs and depreciation, as well as an increase of approximately $82,000 in legal fees.

Sales and Marketing Expenses. Sales and marketing expenses were approximately $3,875,000 for the nine months ended September 30, 2016, compared with approximately $2,616,000 for the nine months ended September 30, 2015, an increase of $1,259,000, or 48%. The increase was primarily due to an increase of approximately $1,021,000 in personnel costs and travel expenses associated with an increase in the average number of employees included in the sales and marketing function from 12 employees during the nine months ended September 30, 2015 to 15 employees during the same period in 2016, as well as an increase of approximately $193,000 in consulting and other third party service provider costs associated with expanded commercial activities.

Our net cash flow from operating, investing and financing activities for the periods below were as follows:

Cash Used in Operating Activities. Net cash used in operating activities was $11.3 million for the nine months ended September 30, 2016, compared to net cash used in operating activities of $10.9 million for the nine months ended September 30, 2015. The net increase of $0.4 million of cash used in operating activities for the nine months ended September 30, 2016 as compared to the same period in 2015 was primarily related to an increase of $1.9 million in cash used to fund our net loss, partially offset by an increase of approximately $1.3 million of cash provided by operating assets and liabilities, as well as an increase of $0.2 million in adjustments to reconcile net loss to net cash used in operating activities primarily related to stock compensation and depreciation expenses.

Cash Used in Investing Activities. Cash used in investing activities of approximately $391,000 and $119,000 during the nine months ended September 30, 2016 and 2015, respectively, was related to the acquisition of fixed assets.

Cash Provided by Financing Activities. Net cash provided by financing activities was $3.5 million for the nine months ended September 30, 2016, compared to net cash provided by financing activities of $18.2 million for the nine months ended September 30, 2015. Our primary sources of cash from financing during the nine months ended September 30, 2015 consisted of proceeds from our public offering in February 2015 and the exercise of common stock warrants sold in that offering. Our primary sources of cash from

financing during the nine months ended September 30, 2016 consisted of $4.3 million in net proceeds from our public offering in May 2016 and $0.5 million in proceeds from the sale of common stock to Aspire Capital under our then-existing common stock purchase agreement, which was partially offset by $1.3 million of principal payments made on indebtedness.

We expect to continue to incur substantial operating losses in the future. It may take several years to achieve positive operational cash flow or we may not ever achieve positive operational cash flow. We expect that we will use a portion of the net proceeds from our follow-on public offerings and our revenues from operations to hire sales and marketing personnel, support increased sales and marketing activities, fund further research and development, clinical utility studies and future enhancements of our assays, acquire equipment, implement automation and scale our capabilities to prepare for significant assay volume, for general corporate purposes and to fund ongoing operations and the expansion of our business, including the increased costs associated with expanded commercial activities. We may also use a portion of the net proceeds from our follow-on public offerings to acquire or invest in businesses, technologies, services or products, although we do not have any current plans to do so.

As of September 30, 2016, our cash and cash equivalents totaled $0.7 million, and our outstanding indebtedness totaled $5.3 million (including $0.2 million of interest accrued thereon, and excluding $0.7 million of associated debt discounts). While we currently are in the commercialization stage of operations, we have not yet achieved profitability and anticipate that we will continue to incur net losses for the foreseeable future. Management expects that we will need additional financing to execute on our current or future business strategies beyond March 2017.

On February 13, 2015, we received net cash proceeds of $9.1 million as a result of the closing of a follow-on public offering, before deducting $0.3 million of additional non-underwriting costs incurred. Subsequent to the closing of this follow-on public offering on February 13, 2015, additional cash proceeds of approximately $9.8 million have been received from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $4.68 per share until their expiration in February 2020.

In May 2015, the SEC declared effective a shelf registration statement filed by us. The shelf registration statement allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as our public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between us and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between us and the purchasers signatory thereto, a public offering of 1,662,191 shares of our common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which we received, after deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to Roth Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.3 million after deducting an estimated $0.3 million of additional third party costs incurred in connection with this offering. An aggregate balance of approximately $0.7 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that our September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as our public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by us under this shelf registration statement. In connection with our public offering in May 2016, we have agreed to certain contractual terms that limit our ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

On December 21, 2015, we entered into a common stock purchase agreement with Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of our common stock over the 30-month term of the common stock purchase agreement. On November 4, 2016, we voluntarily terminated this common stock purchase agreement. Upon execution of the common stock purchase agreement, we sold to Aspire Capital 208,334 shares of common stock at $4.80 per share for gross proceeds of $1,000,000, before deducting approximately $0.1 million of associated costs incurred by third parties, and we concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which we filed a registration statement registering the sale of the shares of our common stock that were issued to Aspire Capital under the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, we issued to Aspire Capital 55,000 shares of our common stock. During the nine months ended September 30, 2016, we submitted purchase notices to Aspire Capital for an aggregate of 173,145 shares of common stock for gross proceeds of $544,051.

On October 19, 2016, we received net cash proceeds of approximately $9.4 million as a result of the closing of a follow-on public offering, before deducting an estimated $0.6 million of additional non-underwriting costs incurred. Subsequent to the closing of this public offering on October 19, 2016, the underwriters have exercised their overallotment option to purchase 627,131 option warrants for total proceeds of $564. As such, warrants to purchase up to 9,727,131 shares of our common stock issued in connection with our October 2016 public offering were outstanding as of the date that our September 30, 2016 financial statements were available to be issued, with approximately $10.7 million in corresponding gross warrant proceeds remaining outstanding and available to be exercised at $1.10 per share until their expiration in October 2021.

We expect that we will need additional financing to execute on our current or future business strategies. Until we can generate significant cash from operations, including assay revenues, we expect to continue to fund operations with the proceeds from offerings of our equity securities or debt, or transactions involving product development, technology licensing or collaboration. For example, we have an effective shelf registration statement on file with the SEC which allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time with an available remaining aggregate initial offering price of up to approximately $39.2 million, subject to certain limitations for so long as our public float is less than $75.0 million. In connection with our public offering in May 2016, we have agreed to certain contractual terms that limit our ability to issue variable rate securities for a period of one year. We can provide no assurances that any sources of a sufficient amount of financing will be available to us on favorable terms, if at all. If we are unable to raise a sufficient amount of financing in a timely manner, we would likely need to scale back our general and administrative activities and certain of our research and development activities. Our forecast pertaining to our current financial resources and the costs to support our general and administrative and research and development activities are forward-looking statements and involve risks and uncertainties. Actual results could vary materially and negatively as a result of a number of factors, including:

We may raise additional capital to fund our current operations and to fund expansion of our business to meet our long-term business objectives through public or private equity offerings, debt financings, borrowings or strategic partnerships coupled with an investment in our company or a combination thereof. If we raise additional funds through the issuance of convertible debt securities, or other debt securities, these securities could be secured and could have rights senior to those of our common stock. In addition, any new debt incurred by us could impose covenants that restrict our operations. The issuance of any new equity securities will also dilute the interest of our current stockholders. Given the risks associated with our business, including our unprofitable operating history and our ability or inability to develop additional assays, additional capital may not be available when needed on acceptable terms, or at all. If adequate funds are not available, we will need to curb our expansion plans or limit our research and development activities, which would have a material adverse impact on our business prospects and results of operations.

We have not engaged in any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

For a discussion of accounting policies that we consider critical to our business operations and understanding of our results of operations, and that affect the more significant judgments and estimates used in the preparation of our financial statements, see Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2015. There

have been no material changes to our critical accounting policies and estimates from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2015.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of September 30, 2016, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2016. There were no changes in our internal control over financial reporting that occurred during the nine months ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

For a discussion of our potential risks and uncertainties, please see the information listed below, along with the information listed in the item captioned “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015. Except as provided below, there have been no material changes to the risk factors as disclosed in the Form 10-K. You should carefully consider the risk factors discussed below and in our Annual Report on Form 10-K for the year ended December 31, 2015, which could materially affect our business, financial position and results of operations.

We expect to continue to incur losses for the foreseeable future and will have to raise additional capital to fund our planned operations and to meet our long-term business objectives. As a result, there is substantial doubt about our ability to continue as a going concern unless we are able to successfully raise additional capital. Until we can generate significant cash from operations, including assay revenues, we expect to continue to fund our operations with the proceeds from offerings of our equity securities or debt, or transactions involving product development, technology licensing or collaboration. We can provide no assurances that any sources of a sufficient amount of financing will be available to us on favorable terms, if at all. Failure to raise additional capital in sufficient amounts would significantly impact our ability to continue as a going concern. The actual amount of funds that we will need and the timing of any such investment will be determined by many factors, some of which are beyond our control.

Our failure to meet the continued listing requirements of The NASDAQ Capital Market could result in a de-listing of our common stock.

If we fail to satisfy the continued listing requirements of The NASDAQ Capital Market, such as the corporate governance requirements, the minimum closing bid price requirement, or the minimum stockholders’ equity requirement, NASDAQ may take steps to de-list our common stock. For example, in May 2016, we received a letter from NASDAQ indicating that we are not in compliance with the minimum stockholders’ equity requirement of NASDAQ Listing Rule 5550(b)(1), and in June 2016, we received a letter from NASDAQ indicating that we are not in compliance with the minimum bid price requirement of NASDAQ Listing Rule 5550(a)(2). If we fail to maintain compliance with these, or any other of the continued listing requirements of The NASDAQ Capital Market, NASDAQ may take steps to de-list our common stock. Such a de-listing would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a de-listing, we would take actions to restore our compliance with NASDAQ’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, or prevent future non-compliance with NASDAQ’s listing requirements.

We recently hired Timothy Kennedy, who serves as our Chief Financial Officer, Senior Vice President of Operations and Secretary. We intend to recruit and hire other senior executives. Such management transitions subject us to a number of risks, including risks pertaining to coordination of responsibilities and tasks, creation of new management systems and processes, differences in management style, effects on corporate culture, and the need for transfer of historical knowledge. In addition, our Chief Executive Officer has not previously been the chief executive officer of a public or private company, and therefore his lack of experience may result in some of his time being spent acclimating to his new position and responsibilities. A lack of significant experience in being the chief executive officer of a public company could have an adverse effect on his ability to quickly respond to problems or effectively manage issues surrounding the operation of a public company.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products and services. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products and services may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products and services. We have conducted freedom to operate analyses with respect to only certain of our products and services, and therefore we do not know whether there are any third-party patents that would impair our ability to commercialize these products and services. We also cannot guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our products and services. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our products or services may infringe.

For example, in August 2016, we received a letter from MolecularMD Corp. offering a license to two U.S. Patents owned by the Memorial Sloan-Kettering Cancer Center, and licensed to MolecularMD Corp., that are relevant to one of the biomarkers we detect in our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target Selector™ Assay and our Liquid Biopsy Lung Cancer Resistance Profile Target Selector™ Assay. One of the two patents is expected to expire in 2026. The other patent is expected to expire in 2028. Although we believe that the claims of both patents relevant to our assays would likely be held invalid, we cannot provide any assurances that a court or an administrative agency would agree with our assessment. If the validity of the relevant claims in question is upheld upon a validity challenge, then we may be liable for past damages and would need a license in order to continue commercializing our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target Selector™ Assay and our Liquid Biopsy Lung Cancer Resistance Profile Target Selector™ Assay in the United States. However, such a license may not be available on commercially reasonable terms or at all, which could materially and adversely affect our business.

In addition, we are aware of a U.S. Patent owned by Amgen, Inc. that is relevant to one of the biomarkers we detect in our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target Selector™ Assay and our Liquid Biopsy Lung Cancer Resistance Profile Target Selector™ Assay. The patent is expected to expire in 2028. Although we believe that the claims of the patent relevant to our assays would likely be held invalid, we cannot provide any assurances that a court or an administrative agency would agree with our assessment. If the validity of the relevant claims in question is upheld upon a validity challenge, then we may be liable for past damages and would need a license in order to continue commercializing our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target Selector™ Assay and our Liquid Biopsy Lung Cancer Resistance Profile Target Selector™ Assay in the United States. However, such a license may not be available on commercially reasonable terms or at all, which could materially and adversely affect our business.

We are also aware of a U.S. Patent owned by Genentech, Inc. that is relevant to one of the biomarkers we detect in our Liquid Biopsy Lung Cancer Resistance Profile Target Selector™ Assay and our Liquid Biopsy Colon Cancer Profile Target Selector™ Assay. The patent is expected to expire in 2025. Although we believe that the claims of the patent relevant to our assays would likely be held invalid, we cannot provide any assurances that a court or an administrative agency would agree with our assessment. If the validity of the relevant claims in question is upheld upon a validity challenge, then we may be liable for past damages and would need a license in order to continue commercializing our Liquid Biopsy Lung Cancer Resistance Profile Target Selector™ Assay and our Liquid Biopsy Colon Cancer Profile Target Selector™ Assay in the United States. However, such a license may not be available on commercially reasonable terms or at all, which could materially and adversely affect our business.

In addition, in July 2016, we received a communication from the Mayo Foundation for Medical Education and Research (“Mayo”) offering a license to a U.S. Patent owned by Mayo that is relevant to an antibody that we use in our Liquid Biopsy Immuno-Oncology PD-L1 Test. The patent is expected to expire in 2021. At present, we believe that we will need a license to this patent to continue commercializing our Liquid Biopsy Immuno-Oncology PD-L1 Test. We are currently in discussions with Mayo and believe a license can be obtained on commercially reasonable terms. However, if we are unable to secure such a license, we may be liable for past damages, and our business could be materially and adversely affected.

In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our products or services, the holders of any such patents may be able to block our ability to commercialize such products or services unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

The exhibits listed on the accompanying index to exhibits immediately preceding the exhibits are filed as part of, or hereby incorporated by reference into, this Quarterly Report.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

The exhibits listed below are hereby filed with the SEC as part of this Quarterly Report on Form 10-Q.

Exhibit No.		Description of Exhibit
10.2+		Biocept, Inc. Amended and Restated 2013 Equity Incentive Plan, Form of Stock Option Grant Notice, Option Agreement, Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit agreement for use thereunder (incorporated by reference to Exhibit 99.3 of the Registrant’s Current Report on Form 8-K (File No. 001-36284), filed with the SEC on July 27, 2016).
31.1		Certification of Michael Nall, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Timothy Kennedy, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Michael Nall, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification of Timothy Kennedy, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

+	Indicates management contract or compensatory plan.

EX-31.1 2 bioc-ex311_7.htm EX-31.1 bioc-ex311_7.htm

EXHIBIT 31.1

CERTIFICATION

I, Michael W. Nall, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2016

/s/ Michael W. Nall

Michael W. Nall

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 bioc-ex312_9.htm EX-31.2 bioc-ex312_9.htm

EXHIBIT 31.2

CERTIFICATION

I, Timothy Kennedy, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 10, 2016

/s/ Timothy Kennedy

Timothy Kennedy

Chief Financial Officer, Senior Vice President of Operations

(Principal Financial and Accounting Officer)

EX-32.1 4 bioc-ex321_6.htm EX-32.1 bioc-ex321_6.htm

EXHIBIT 32.1

CERTIFICATION

I, Michael W. Nall, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended September 30, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: November 10, 2016

/s/ Michael W. Nall

Michael W. Nall

President and Chief Executive Officer

(Principal Executive Officer)

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.

EX-32.2 5 bioc-ex322_10.htm EX-32.2 bioc-ex322_10.htm

EXHIBIT 32.2

CERTIFICATION

I, Timothy Kennedy, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended September 30, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: November 10, 2016		/s/ Timothy Kennedy
		Timothy Kennedy
		Chief Financial Officer, Senior Vice President of Operations
		(Principal Financial and Accounting Officer)

EX-101.INS 6 bioc-20160930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure bioc:Plan utr:sqft bioc:Director bioc:Consultant 0001044378 2016-01-01 2016-09-30 0001044378 2016-11-04 0001044378 2015-12-31 0001044378 2016-09-30 0001044378 2015-07-01 2015-09-30 0001044378 2016-07-01 2016-09-30 0001044378 2015-01-01 2015-09-30 0001044378 2014-12-31 0001044378 2015-09-30 0001044378 bioc:AegisCapitalCorpMember 2015-02-13 0001044378 2015-02-13 0001044378 us-gaap:OverAllotmentOptionMember 2016-09-30 0001044378 2014-12-30 2014-12-31 0001044378 2016-05-04 0001044378 2016-05-03 2016-05-04 0001044378 2014-01-01 2014-12-31 0001044378 2015-01-01 2015-12-31 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember us-gaap:SubsequentEventMember 2016-10-19 0001044378 us-gaap:SubsequentEventMember 2016-10-19 0001044378 us-gaap:SubsequentEventMember 2016-10-18 2016-10-19 0001044378 us-gaap:MaximumMember us-gaap:SubsequentEventMember 2016-10-19 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember 2016-09-29 2016-09-30 0001044378 bioc:OverallotmentOptionsOverallotmentWarrantsAndNonOverallotmentWarrantsMember 2016-01-01 2016-09-30 0001044378 2016-09-26 2016-09-27 0001044378 us-gaap:MinimumMember 2016-09-27 0001044378 us-gaap:MaximumMember 2016-09-27 0001044378 bioc:TwoThousandAndFourteenCreditFacilityMember 2016-09-30 0001044378 2016-02-29 0001044378 us-gaap:MinimumMember 2016-02-01 2016-02-29 0001044378 2015-02-12 2015-02-13 0001044378 us-gaap:MaximumMember bioc:ShelfRegistrationStatementMember 2015-05-31 0001044378 bioc:ShelfRegistrationStatementMember 2015-05-31 0001044378 bioc:ShelfRegistrationStatementMember 2016-05-03 2016-05-04 0001044378 bioc:ShelfRegistrationStatementMember 2016-05-04 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember us-gaap:SubsequentEventMember 2016-10-13 2016-10-14 0001044378 bioc:RothCapitalPartnersLLCAndFeltlMember us-gaap:SubsequentEventMember 2016-10-14 0001044378 bioc:AegisCapitalCorpAndFeltlMember 2015-02-08 2015-02-09 0001044378 bioc:AegisCapitalCorpAndFeltlMember 2015-02-13 0001044378 2015-02-08 2015-02-09 0001044378 bioc:ShelfRegistrationStatementMember 2016-05-31 0001044378 bioc:ShelfRegistrationStatementMember 2016-05-01 2016-05-31 0001044378 bioc:AspireCapitalFundLLCMember us-gaap:CommonStockMember 2015-12-20 2015-12-21 0001044378 bioc:AspireCapitalFundLLCMember us-gaap:CommonStockMember 2015-12-21 0001044378 bioc:AspireCapitalFundLLCMember 2015-12-20 2015-12-21 0001044378 us-gaap:MinimumMember bioc:AspireCapitalFundLLCMember 2015-12-21 0001044378 bioc:AspireCapitalFundLLCMember 2015-12-21 0001044378 bioc:CommonStockPurchaseAgreementMember 2016-01-01 2016-09-30 0001044378 us-gaap:WarrantMember 2016-05-04 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember bioc:ScenarioOneMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember bioc:ScenarioTwoMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember bioc:DebtInstrumentWithRepaymentPeriodTwoMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember 2016-01-01 2016-09-30 0001044378 us-gaap:MinimumMember 2016-01-01 2016-09-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:ScenarioForecastMember 2016-12-30 2016-12-31 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2016-09-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:MinimumMember 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:CommonStockMember 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:CommonStockMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2014-12-31 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2014-01-01 2014-12-31 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2015-12-31 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember us-gaap:MinimumMember 2016-01-01 2016-09-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2015-07-01 2015-09-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-07-01 2016-09-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2015-01-01 2015-09-30 0001044378 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-01-01 2016-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PreReverseStockSplitMember 2016-07-25 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:PostReverseStockSplitMember 2016-07-25 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-09-26 2016-09-27 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember us-gaap:MaximumMember 2016-09-27 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember us-gaap:MinimumMember 2016-09-27 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember us-gaap:MaximumMember 2016-09-27 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember us-gaap:MinimumMember 2016-09-27 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2016-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2016-01-01 2016-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember 2016-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember 2016-01-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001044378 us-gaap:MinimumMember 2016-09-30 0001044378 us-gaap:MaximumMember 2016-09-30 0001044378 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001044378 us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember 2015-08-30 2015-08-31 0001044378 us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:EmployeeStockOptionMember 2016-02-28 2016-02-29 0001044378 us-gaap:EmployeeStockOptionMember bioc:MinimumNumberOfAccessionsProcessedBilledAndCollectedInFiscalTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-01-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember bioc:MinimumRevenuesFromContractsWithPharmaceuticalCompaniesInFiscalTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-01-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember bioc:AttainmentOfSustainablePositiveGAAPGrossMarginByDecemberThirtyOneTwoThousandSixteenMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-01-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember bioc:MinimumOperatingCashOnHandAtDecemberThirtyOneTwoThousandSixteenWithNoMoreThanOneInterimDilutiveEquityFinancingEventMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-01-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember bioc:AchievementOfCompanySTwoThousandAndSixteenCorporateGoalsMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-01-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember bioc:CompletionOfBoardApprovedStrategicTransactionMember us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember 2016-01-01 2016-09-30 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-07-25 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-07-24 2016-07-25 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-07-29 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-07-28 2016-07-29 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2016-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2014-06-11 2014-06-12 0001044378 bioc:MinimumRevenueInTwoThousandFifteenMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 bioc:MaximumEBITDALossInTwoThousandFifteenMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 bioc:AttainmentOfFinancialPlanForFiscalTwoThousandFifteenMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 bioc:MinimumValueOfStrategicAgreementsByDecemberThirtyOneTwoThousandFifteenMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 bioc:ImplementationOfFourNewDiagnosticTestPanelsByDecemberThirtyOneTwoThousandFifteenMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-09-30 0001044378 us-gaap:ExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:RetentionRestrictedStockUnitsRSUMember 2016-07-05 2016-07-06 0001044378 us-gaap:ChiefExecutiveOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:RetentionRestrictedStockUnitsRSUMember 2016-07-05 2016-07-06 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:RetentionRestrictedStockUnitsRSUMember 2016-07-05 2016-07-06 0001044378 us-gaap:ChiefFinancialOfficerMember bioc:TwoThousandThirteenEquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2016-07-24 2016-07-25 0001044378 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001044378 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001044378 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001044378 us-gaap:CostOfSalesMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001044378 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001044378 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001044378 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001044378 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2016-07-01 2016-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001044378 us-gaap:CostOfSalesMember us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0001044378 us-gaap:CostOfSalesMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0001044378 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0001044378 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 us-gaap:SellingAndMarketingExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0001044378 us-gaap:SellingAndMarketingExpenseMember us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2016-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2015-01-01 2015-09-30 0001044378 bioc:StockOptionsAndRestrictedStockUnitsMember 2016-09-30 0001044378 us-gaap:MinimumMember 2015-07-01 2015-09-30 0001044378 us-gaap:MinimumMember 2016-07-01 2016-09-30 0001044378 us-gaap:MinimumMember 2015-01-01 2015-09-30 0001044378 us-gaap:MaximumMember 2015-07-01 2015-09-30 0001044378 us-gaap:MaximumMember 2016-07-01 2016-09-30 0001044378 us-gaap:MaximumMember 2015-01-01 2015-09-30 0001044378 us-gaap:WarrantMember 2015-12-31 0001044378 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001044378 us-gaap:WarrantMember 2016-09-30 0001044378 us-gaap:WarrantMember 2015-01-01 2015-12-31 0001044378 bioc:PreferredStockWarrantsMember 2015-07-01 2015-09-30 0001044378 bioc:PreferredStockWarrantsMember 2016-07-01 2016-09-30 0001044378 bioc:RestrictedPreferredStockMember 2015-07-01 2015-09-30 0001044378 bioc:WarrantsOutstandingMember 2015-07-01 2015-09-30 0001044378 bioc:WarrantsOutstandingMember 2016-07-01 2016-09-30 0001044378 bioc:RestrictedCommonStockMember 2015-07-01 2015-09-30 0001044378 bioc:RestrictedCommonStockMember 2016-07-01 2016-09-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2015-07-01 2015-09-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2016-07-01 2016-09-30 0001044378 bioc:PreferredStockWarrantsMember 2015-01-01 2015-09-30 0001044378 bioc:PreferredStockWarrantsMember 2016-01-01 2016-09-30 0001044378 bioc:RestrictedPreferredStockMember 2015-01-01 2015-09-30 0001044378 bioc:WarrantsOutstandingMember 2015-01-01 2015-09-30 0001044378 bioc:WarrantsOutstandingMember 2016-01-01 2016-09-30 0001044378 bioc:RestrictedCommonStockMember 2015-01-01 2015-09-30 0001044378 bioc:RestrictedCommonStockMember 2016-01-01 2016-09-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2015-01-01 2015-09-30 0001044378 bioc:CommonStockOptionsOutstandingMember 2016-01-01 2016-09-30 0001044378 2016-02-01 2016-02-29 0001044378 us-gaap:DirectorMember 2015-02-08 2015-02-09 0001044378 us-gaap:DirectorMember 2015-02-09 0001044378 bioc:AegeaBiotechnologiesIncMember 2016-01-01 2016-09-30 0001044378 bioc:SanDiegoCaliforniaFacilityMember bioc:NonExecutiveMember 2016-09-30 0001044378 bioc:NonExecutiveMember 2016-01-01 2016-09-30 0001044378 bioc:NonExecutiveMember 2016-09-30 0001044378 us-gaap:DirectorMember 2016-05-03 2016-05-04 0001044378 us-gaap:DirectorMember 2016-05-04 0001044378 us-gaap:MajorityShareholderMember 2016-05-03 2016-05-04 0001044378 us-gaap:MajorityShareholderMember 2016-05-04 0001044378 us-gaap:SubsequentEventMember 2016-10-14 0001044378 us-gaap:SubsequentEventMember 2016-10-13 2016-10-14 0001044378 us-gaap:MaximumMember us-gaap:SubsequentEventMember 2016-10-14 0001044378 us-gaap:OverAllotmentOptionMember us-gaap:SubsequentEventMember 2016-10-14 0001044378 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2016-10-14 0001044378 us-gaap:OverAllotmentOptionMember us-gaap:SubsequentEventMember 2016-10-13 2016-10-14 0001044378 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2016-10-13 2016-10-14 0001044378 us-gaap:DirectorMember us-gaap:SubsequentEventMember us-gaap:ChiefExecutiveOfficerMember 2016-10-13 2016-10-14 0001044378 us-gaap:DirectorMember us-gaap:SubsequentEventMember 2016-10-13 2016-10-14 0001044378 us-gaap:DirectorMember us-gaap:SubsequentEventMember 2016-10-14 0001044378 us-gaap:MajorityShareholderMember us-gaap:SubsequentEventMember 2016-10-13 2016-10-14 0001044378 bioc:ConsultantMember us-gaap:SubsequentEventMember 2016-10-13 2016-10-14 0001044378 us-gaap:MajorityShareholderMember us-gaap:SubsequentEventMember 2016-10-14 0001044378 bioc:ConsultantMember us-gaap:SubsequentEventMember 2016-10-14 0001044378 us-gaap:SubsequentEventMember 2016-10-20 2016-11-09 0001044378 us-gaap:CommonStockMember bioc:AspireCapitalFundLLCMember 2016-01-01 2016-09-30 10-Q false 2016-09-30 2016 Q3 BIOC BIOCEPT INC 0001044378 --12-31 Smaller Reporting Company 17499397

8821329

678855

34200

85664

349271

497517

435938

499133

9640738

1761169

946180

1521380

10586918

3282549

632538

1700383

966899

1143863

42369 48880

110924

255605

1588058

1896718

3340788

5045449

291189

572096

2638487

1593220

153547 209914

470172

418028

6894183

7838707

656

840

158928627

164891998

-155236548

-169448996

3692735

-4556158

10586918

3282549

0.0001

40000000

150000000

6556685

8399397

6556685

8399397

164856

1047280

391626

1931509

1159710

1876288

3320467

5020649

677729

600613

2073391

2044968

1630608

1919843

4281883

4924731

1055653

1278455

2616218

3875063

4523700

5675199

12291959

15865411

-4358844

-4627919

-11900333

-13933902

175562

154869

494235

393029

38412

64020

115236

1300

-137150

-115157

-430215

-276493

-4495994

-4743076

-12330548

-14210395

199

1478

2053

-4496193

-4743076

-12332026

-14212448

6242604

8370691

5245303

7549663

6242604

8370691

5245303

7549663

-0.72

-0.57

-2.35

-1.88

-0.72

-0.57

-2.35

-1.88

188120

248164

20277 40708

1016266

1164979

93454

60951

29760

51464

93000

107538

181284

-501532

142028

991846

218468

152860

96295

58684

5614

-22839

-10896102

-11257281

1300

118896

392496

-118896

-391196

8830057 4798576

9697660

54007

86336

33674

427934

247701

778303

18192335

3506003

7177337

-8142474

5364582

12541919

309324

282142

2054

2053

2666666

4.68

P5Y 7700000 P45D 400000 3.75 400000

0.0003

1600000 63111 1163526

3.90

P5Y 2000000 279008 631232 126811

19546

3190

64300

8637

434475 9100000 0.57 5200000 P30D 1365000 1.0331 1365000

0.0009

627131

564

800000

1.10

P5Y 130252 0

<div> 8. Stock-based Compensation On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The following per share amounts and share numbers have been adjusted for this reverse stock split as if it had occurred on January 1, 2015. Equity Incentive Plans The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 1,000,000 shares on a pre-reverse stock split basis, or 333,333 shares on a post-reverse stock split basis, of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. In conjunction with the one-for-three reverse split of the Company’s common stock effected on September 27, 2016, the number of non-inducement shares authorized under all plans decreased from 3,068,865 to 1,022,955 shares, and the number of inducement shares authorized under the 2013 Plan decreased from 1,000,000 shares to 333,333 shares. As of September 30, 2016, under all plans, a total of 1,022,955 non-inducement shares were authorized for issuance, 978,358 non-inducement stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 3,115 non-inducement shares were available for grant. As of September 30, 2016, a total of 333,333 inducement shares were authorized for issuance, 124,999 inducement stock options and RSUs had been issued and were outstanding, and 208,334 inducement shares were available for grant under the 2013 Plan. Stock Options A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646,900</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.48</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.0</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713,659</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.23</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">276,628</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.60</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited/expired</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,679</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.08</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">926,608</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.87</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, September 30, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838,037</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.37</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The intrinsic values of options outstanding and options vested and unvested expected to vest at September 30, 2016 were both zero. The intrinsic value of options exercisable at September 30, 2016 was zero. The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock and exercise prices</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.57 - $4.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.99% – 1.39%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.13 – 6.08</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.0% - 90.0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the nine months ended September 30, 2016 was $1.86 per share. On August 31, 2015, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $4.40 per share to its Chief Executive Officer pursuant to the 2013 Plan. On February 29, 2016, the Company’s Board of Directors approved the issuance of 33,333 stock options with an estimated grant date fair value of $2.87 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall Stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Grants</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to Vesting</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum number of accessions processed, billed and collected</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenues from contracts with pharmaceutical <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   companies</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attainment of a sustainable positive GAAP gross  margin</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum operating cash on-hand with no more than one interim <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   dilutive equity financing event</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achievement of the Company's 2016 corporate goals</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completion of a Board-approved strategic transaction</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> On July 25, 2016, the Company entered into an employment agreement with its new Chief Financial Officer, Senior Vice President of Operations and Secretary, or CFO. Pursuant to the terms of this employment agreement, on July 29, 2016 the CFO was granted inducement stock option awards to purchase up to (i) 66,666 shares of the Company’s common stock with an estimated grant date fair value of $1.45 per share, 25% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company, and remainder of which will vest in equal monthly installments over the following three years, and (ii) 33,333 shares of the Company’s common stock with an estimated grant date fair value of $1.26 per share, which vest upon the Company’s achievement of specified corporate goals for 2016 and the consummation of a specified financing transaction. Restricted Stock   A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, December 31, 2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.49</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,752</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,829</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and issued</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,449</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.05</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,383</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.05</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,749</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.70</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, September 30, 2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,550</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.71</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The RSUs granted during the nine months ended September 30, 2016 vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. At September 30, 2016, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were $277,496 and $270,904, respectively. On June 12, 2014, the Company’s Board of Directors granted an RSU award for 14,832 shares with a grant date fair value of $16.05 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall RSU</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Subject to</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenue</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maximum EBITDA loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attainment of financial plan for fiscal 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum value of strategic agreements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of four new diagnostic test panels</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> During the nine months ended September 30, 2016, a total of 4,449 RSUs were declared vested by the Company’s Board of Directors and issued to its Chief Executive Officer in satisfaction of this award and the remaining 10,383 shares underlying this RSU were forfeited. On July 6, 2016, the Compensation Committee of the Company’s Board of Directors approved retention RSUs for an aggregate of 58,332 shares of common stock to three of the Company’s executive officers pursuant to the 2013 Plan, including retention RSUs for 25,000 shares of common stock to its Chief Executive Officer. Each of these retention RSUs has a grant date fair value of $1.86 per share for a grant date fair value of $108,498 to all three officers, in aggregate. These retention RSUs vest fully on the one year anniversary of the date of grant, subject to continuing service by the holders of such RSUs. Pursuant to the terms of the Company’s employment agreement with its CFO dated July 25, 2016, the CFO was granted an inducement RSU award on July 29, 2016 covering 25,000 shares of the Company’s common stock with a grant date fair value of $1.95 per share, 100% of which will vest on the one-year anniversary of the commencement of the CFO’s employment with the Company. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,029</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,119</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,839</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,606</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,910</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,189</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,835</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,153</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,404</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292,381</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">706,026</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">829,516</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,888</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,924</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,989</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,164</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses related to stock options</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325,231</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,613</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">914,689</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097,439</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,918</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,834</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,131</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,724</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,583</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,515</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,668</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,853</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,676</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,939</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,447</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339,371</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,269</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016,266</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,164,979</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 4% and 0% - 8% per annum during the three and nine months ended September 30, 2015 and 2016, respectively. As of September 30, 2016, total unrecognized stock-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,081,000 and is expected to be recognized over a weighted-average period of 2.1 years. </div>

<div> Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.   On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock, which was not affected by the one-for-three reverse stock split. </div>

<div> Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended September 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.</div>

<div> The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments. </div>

<div> the estimated grant date fair value of $1.72 per share associated with the warrants to purchase 1,163,526 shares of common stock issued in such offering, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.70</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.90</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> The following provides certain balance sheet details:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.16%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</td> <td colspan="6" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,518,158</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,707,601</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,726</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,726</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">577,898</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">617,802</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,614</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517,968</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financed equipment</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">914,179</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,457,377</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,815</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,280</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,739,390</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,562,754</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,793,210</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,041,374</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fixed assets, net</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">946,180</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521,380</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued Liabilities</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued interest</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,825</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,753</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301,988</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued vacation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">307,845</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313,825</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonuses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376,100</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,237</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales commissions</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,574</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,844</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.88%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred rent</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,170</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.16%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,475</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,476</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.16%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,669</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.88%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">966,899</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.16%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,143,863</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following schedule sets forth the future minimum lease payments, as well as corresponding laboratory equipment maintenance obligations that are not recorded as part of the leased equipment balances within fixed assets or capital lease obligations, outstanding under capital leases and due within each respective year ending December 31, and the present value of the minimum lease payments as of September 30, 2016: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maintenance</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Obligation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,754</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,375</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">238,287</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,440</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190,333</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,434</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155,388</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,676</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,400</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,608</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">374,005</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,471</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,178,167</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166,004</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amount representing interest</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,466</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827,701</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166,004</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">646,900</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.48</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.0</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">713,659</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.23</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">276,628</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.60</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited/expired</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,679</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.08</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">926,608</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.87</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:56.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, September 30, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838,037</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.37</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.52%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock and exercise prices</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.57 - $4.02</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.99% – 1.39%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.13 – 6.08</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.7%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.0% - 90.0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall Stock</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Grants</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.36%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to Vesting</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum number of accessions processed, billed and collected</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenues from contracts with pharmaceutical <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   companies</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attainment of a sustainable positive GAAP gross  margin</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum operating cash on-hand with no more than one interim <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   dilutive equity financing event</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:78.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achievement of the Company's 2016 corporate goals</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Completion of a Board-approved strategic transaction</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:78.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percentage of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overall RSU</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Subject to</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Target</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum revenue</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maximum EBITDA loss</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attainment of financial plan for fiscal 2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:77.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum value of strategic agreements</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Implementation of four new diagnostic test panels</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:77.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

<div> A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, December 31, 2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,369</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.49</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,752</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165,829</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.96</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and issued</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,449</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.05</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,383</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.05</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,749</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.70</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest, September 30, 2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,550</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.71</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,029</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,119</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,839</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,606</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,910</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,189</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,835</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,153</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,404</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292,381</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">706,026</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">829,516</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,888</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,924</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,989</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,164</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses related to stock options</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325,231</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">406,613</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">914,689</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097,439</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,918</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,834</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,625</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,131</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,724</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,583</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,515</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,668</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,853</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,676</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,939</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,447</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339,371</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,269</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016,266</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,164,979</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> On September 27, 2016, the Company effected a one-for-three reverse stock split of all common shares outstanding. The summary of equity-classified common stock warrant activity has been adjusted for this reverse stock split as if it had occurred on December 31, 2015. A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2016 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.92%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.3%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.34%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.34%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.34%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.1%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.34%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.62%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">784,234</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.19</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,163,526</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.3%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.90</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.34%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.3%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.34%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.58%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.92%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,904</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.34%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.58%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.92%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,896,856</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.21</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.58%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.7%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three and nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.58%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred warrants outstanding (number of common stock equivalents)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">529</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred share RSUs (number of common stock equivalents)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,384</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common warrants outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">797,579</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,896,856</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common share RSUs</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,752</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">176,749</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.72%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common options outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">684,779</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">926,608</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total anti-dilutive common share equivalents</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,533,023</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000,742</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.72%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> The fair values of these overallotment options and all warrants issued in the October 2016 offering were estimated using Black-Scholes valuation models with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.28%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overallotment Options</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.93</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0331</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.10</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.24</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.08</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.16%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  </div>

0.33

40000000

150000000

-16900000

5300000 2200000 2800000

1062500

62500 Quarterly

2020-05-31

9800000

2700000 4.68 2020-02 50000000 75000000 4300000

4500000 3.90 2021-05 75000000 P1Y

9100000

1.10

10000000

2666666

3.75

9100000

8800000

300000

P45D 400000 400000 3.75

0.0003

1600000

200000

700000 300000 18600000 900000 75000000 P1Y 2016-04-25 2016-04-29 1662191 1163526

3.00

3.90

4600000

4300000

300000

700000

4500000

15000000

P30M

208334

4.80

1000000

33333 15000000 P10D

1.50

0.30 0.97

1.50

55000

173145

544051

42000

83000

1400000

1.72

2.70

3.90

0.0000

0.0123

P5Y

0.900

2518158

2707601

143726

577898 617802

514614

517968

914179

1457377

70815

118280

4739390

5562754

3793210

4041374

28981

23825

128753

301988

307845

313825

376100

318237

76574

97844

31170

60475

17476

27669

4898000

50000

0.0795

0.0771

0.0795

0.055 0.01 50000

7000000

75000

1200000

250000 250000

17655

14.16

P10Y

102498

4897502 233107

0.1387

0.1150

P5Y

P7Y

523000

616000

24000

40000

49000

93000

0.1335 2017-07 2023-05

68754

238287

190333

155388

151400

374005

1178167

350466

827701

6375 25440 25434 24676 24608 59471 166004 166004 255605 2

1000000

333333

0.33

3068865

1022955

1000000

333333

1022955

978358

3115

333333

124999

208334

646900

713659

276628

63679

926608

838037

15.48

11.23

2.60

8.08

8.87

9.37

P9Y

P8Y8M12D

P8Y1M6D

Black-Scholes pricing model

1.57

4.02

0.0000

0.0099 0.0139

P5Y1M17D

P6Y29D

0.8000

0.9000

1.86

33333

4.40

2.87

0.13

0.10

0.12

0.15

0.25

1.00

66666

1.45

0.25

P1Y

P3Y

33333

1.26

15369

25752

165829

4449

10383

176749

172550 14.49

15.12

1.96

16.05

2.70

2.71

P1Y

277496

270904

14832

16.05

0.25

0.15

0.20

1.00

4449

58332

25000

1.86

108498

P1Y

25000

1.95

1.00

P1Y

15029

34119

48839

89606

20910

28189

65835

87153

257404

292381

706026

829516

31888

51924

93989

91164

325231

406613

914689

1097439

14918

16834

1625

14131

10724

15583

12515

6668

90853

7676

22939

27447

339371

465269

1016266

1164979

2081000

P2Y1M6D

0.00 0.00 0.00 0.00 0.04 0.08 0.04 0.08

784234

1163526 50904

1896856

11.19 3.90 30.00 6.21 P3Y9M18D P4Y1M6D 0 0

529

24384

797579

1896856

25752

176749

684779

926608

1533023

3000742

529

24384

797579

1896856

25752

176749

684779

926608

1533023

3000742

62500

47331

177500

19047

9849

2015-03-30 12804

12804

2015-07-31

58335

40832

175000

204758

143330

614273

0.57 5200000 P30D 1365000 1.0331 1365000

0.0009

627131

564

800000

1.10

P5Y

0.93

1.0331

1.10

0.0000

0.0025

0.0124

P29D

P5Y

0.129

0.800

7 3

534088

587497

227272

79090

227272 79090

249999

86999

600000

9400000

8800000

600000

600000 2016-11-04

EX-101.SCH 7 bioc-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Liquidity and Going Concern Uncertainty link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Sales of Equity Securities link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value Measurement link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - April 2014 Credit Facility link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Capital Lease Obligations link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Stock-based Compensation link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Common Stock Warrants Outstanding link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Net Loss per Common Share link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Fair Value Measurement (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Capital Lease Obligations (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Stock-based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Common Stock Warrants Outstanding (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Net Loss per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Subsequent Events (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Liquidity and Going Concern Uncertainty- Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Sales of Equity Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - April 2014 Credit Facility - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Capital Lease Obligations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Capital Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Lease Obligations (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Stock-based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Stock-based Compensation - Summary of RSU Activity for Awards Granted (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Common Stock Warrants Outstanding - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Net Loss per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Subsequent Events - Assumptions Used for Determining Fair Values of Overallotment Options, Overallotment Warrants and Non-overallotment Warrants Issued (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 bioc-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 bioc-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 bioc-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document and entity information. Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Supplier financings. Carrying value as of the balance sheet date of noncurrent portion of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Statement Of Financial Position [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Inventories, net Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Fixed assets, net Property Plant And Equipment Net Total assets Assets Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Supplier financings Supplier Financings Current portion of equipment financings Capital Lease Obligations Current Current portion of credit facility Lines Of Credit Current Total current liabilities Liabilities Current Non-current portion of equipment financings, net Capital Lease Obligations Noncurrent Non-current portion of credit facility, net Long Term Line Of Credit Non-current portion of interest payable Interest Payable Noncurrent Non-current portion of deferred rent Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies (see Note 11) Commitments And Contingencies Shareholders’ equity/(deficit): Stockholders Equity [Abstract] Common stock, $0.0001 par value, 40,000,000 authorized; 6,556,685 issued and outstanding at December 31, 2015; 150,000,000 authorized; 8,399,397 issued and outstanding at September 30, 2016. Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders’ equity/(deficit) Stockholders Equity Total liabilities and shareholders’ equity/(deficit) Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenues: Revenues Costs and expenses: Costs And Expenses [Abstract] Cost of revenues Cost Of Revenue Research and development expenses Research And Development Expense General and administrative expenses General And Administrative Expense Sales and marketing expenses Selling And Marketing Expense Total costs and expenses Costs And Expenses Loss from operations Operating Income Loss Other income/(expense): Nonoperating Income Expense [Abstract] Interest expense, net Interest Expense Other income Other Income Gain on sale of fixed assets Gain Loss On Disposition Of Assets1 Total other income/(expense): Nonoperating Income Expense Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense Income Tax Expense Benefit Net loss and comprehensive loss Net Income Loss Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders: Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Net loss per common share: Earnings Per Share [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Increase decrease in inventory reserve. Proceeds from issuance of common stock and warrants. Cash paid during period. Statement Of Cash Flows [Abstract] Cash Flows from Operating Activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Inventory reserve Increase Decrease In Inventory Reserve Stock-based compensation Share Based Compensation Non-cash interest expense related to credit facility and other financing activities Paid In Kind Interest Gain on sale of fixed assets Increase/(decrease) in cash resulting from changes in: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Accrued interest Increase Decrease In Interest Payable Net Deferred rent Increase Decrease In Deferred Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash Flows from Investing Activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Proceeds from sale of fixed assets Proceeds From Sale Of Property Plant And Equipment Purchases of fixed assets Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash Flows from Financing Activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Net proceeds from issuance of common stock and warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from exercise of common stock warrants Proceeds From Warrant Exercises Payments on equipment financings Repayments Of Long Term Capital Lease Obligations Payments on supplier and other third party financings Repayments Of Other Debt Payments on line of credit Repayments Of Lines Of Credit Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net increase (decrease) in Cash and Cash Equivalents Cash And Cash Equivalents Period Increase Decrease Cash and Cash Equivalents at Beginning of Period Cash and Cash Equivalents at End of Period Supplemental Disclosures of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Cash Paid During Period [Abstract] Interest Interest Paid Net Taxes Income Taxes Paid Net Issuance of warrants to purchase common stock shares. Class of warrant or right expiry period. Shares issued to underwriters under over allotment options grant date fair value. Underwriter common stock grants period. Common shares issuable to underwriters under granted option. Shares issued to underwriters under over allotment options per share. Common shares issuable to underwriters under warrants granted. Warrants issued grant date fair value. Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs. Statement [Table] Statement [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Overallotment Options [Member] Over Allotment Option [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Aegis Capital Corp. Aegis Capital Corp [Member] Aegis Capital Corp [Member] Range Range [Axis] Range Range [Member] Maximum [Member] Maximum [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Roth Capital Partners, LLC and Feltl. Roth Capital Partners, LLC and Feltl [Member] Roth Capital Partners L L C And Feltl [Member] Statement [Line Items] Statement [Line Items] Issuance of warrants to purchase shares of common stock Issuance Of Warrants To Purchase Common Stock Shares Exercise price of warrants Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants to purchase common stock, period Class Of Warrant Or Right Expiry Period Purchase of common stock by underwriters to cover overallotments, grant date fair value Shares Issued To Underwriters Under Over Allotment Options Grant Date Fair Value Overallotment issued to underwriter to purchase common stock, period Underwriter Common Stock Grants Period Common shares issuable to underwriters under granted option Common Shares Issuable To Underwriters Under Granted Option Purchase of common stock by underwriters to cover overallotments, per share Shares Issued To Underwriters Under Over Allotment Options Per Share Common Shares issuable to underwriters under warrants granted Common Shares Issuable To Underwriters Under Warrants Granted Issuance of warrants to purchase shares of common stock, grant date fair value Warrants Issued Grant Date Fair Value Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs Offering Costs Recorded In Prepaid Expenses And Other Current Assets Reclassified To Common Stock Issuance Costs Fixed assets purchased under capital lease obligations. Fixed assets with remaining net book value under capital lease obligations. Fixed assets purchased under capital lease obligations Fixed Assets Purchased Under Capital Lease Obligations Fixed assets with a remaining net book value under capital lease obligations Fixed Assets With Remaining Net Book Value Under Capital Lease Obligations Financial Guarantee Insurance Contracts Premium Payable. Purchases of fixed assets Capital Expenditures Incurred But Not Yet Paid Financed insurance premium through third party financing Financial Guarantee Insurance Contracts Premium Payable Estimated grant date fair value of warrants. Shares issued to underwriters under over allotment options. Class of warrant or rights, term Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs paid net. Estimated grant date fair value of warrants Estimated Grant Date Fair Value Of Warrants Purchase of common stock by underwriters to cover overallotments, number of shares Shares Issued To Underwriters Under Over Allotment Options Class of warrant or rights, term Class Of Warrant Or Rights Term Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs paid net Offering Costs Recorded In Prepaid Expenses And Other Current Assets Reclassified To Common Stock Issuance Costs Paid Net Accounting Policies [Abstract] Basis of Presentation Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Liquidity and going concern uncertainty. Liquidity and Going Concern Uncertainty Liquidity And Going Concern Uncertainty Disclosures [Text Block] Sales of equity securities. Equity [Abstract] Sales of Equity Securities Disclosure [Text Block] Sales Of Equity Securities Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurement Fair Value Disclosures [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Credit facility disclosure. Debt Disclosure [Abstract] April 2014 Credit Facility Credit Facility Disclosure [Text Block] Capital Lease Obligations [Abstract] Capital Lease Obligations Capital Leases In Financial Statements Of Lessor Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Common stock warrants outstanding disclosure. Other Liabilities Disclosure [Abstract] Common Stock Warrants Outstanding Common Stock Warrants Outstanding Disclosure [Text Block] Net Loss per Common Share Earnings Per Share [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Nature of operations. The Company and Business Activities Nature Of Operations Policy [Text Block] Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Fair Value Measurement Fair Value Measurement Policy Policy [Text Block] Assumptions Used for Determining Fair Values of Common Stock Warrants Fair Value Inputs Instruments Classified In Shareholders Equity Quantitative Information Table [Text Block] Schedule of Fixed Assets and Accrued Liabilities Schedule Of Condensed Balance Sheet Table [Text Block] Schedule of Future Minimum Lease Payments for Capital Lease Obligations Schedule Of Future Minimum Lease Payments For Capital Leases Table [Text Block] Summary of Stock Option Activity for Option Awards Granted Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Schedule of performance stock options vesting percentage. Schedule of Performance Stock Options Vesting Percentage Schedule Of Performance Stock Options Vesting Percentage Table [Text Block] Summary of RSU Activity for Awards Granted Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of common stock warrants activity. Equity classified warrants. Equity Classified Warrants [Abstract] Summary of Equity-Classified Common Stock Warrant Activity Schedule Of Common Stock Warrants Activity Table [Text Block] Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Overallotment options, overallotment warrants and non-overallotment warrants. Overallotment Options, Overallotment Warrants and Non-overallotment Warrants [Member] Overallotment Options Overallotment Warrants And Non Overallotment Warrants [Member] Summary of significant accounting policies. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Minimum [Member] Minimum [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Stockholders equity reverse stock split ratio Stockholders Equity Note Stock Split Conversion Ratio1 Description of reverse stock split Stockholders Equity Reverse Stock Split Aggregate gross interest-bearing indebtedness. Due within one year. Other non interest bearing liabilities. Unconditional purchase commitment quarterly payment amount. Unconditional purchase commitment frequency of periodic payment. Cash And Cash Equivalents [Abstract] Liquidity and managements plans. Schedule of liquidity and managements plans table. Schedule Of Liquidity And Managements Plans [Table] Schedule Of Liquidity And Managements Plans [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Two thousand and fourteen credit facility. April 2014 Credit Facility [Member] Two Thousand And Fourteen Credit Facility [Member] Shelf registration statement. Shelf Registration Statement [Member] Shelf Registration Statement [Member] Liquidity And Managements Plans [Line Items] Liquidity And Managements Plans [Line Items] Aggregate gross interest-bearing indebtedness Aggregate Gross Interest Bearing Indebtedness Due within one year Due Within One Year Other non-interest bearing liabilities Other Non Interest Bearing Liabilities Unconditional purchase commitment aggregate amount EX-101.PRE 11 bioc-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 04, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,499,397

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 678,855	$ 8,821,329
Accounts receivable	85,664	34,200
Inventories, net	497,517	349,271
Prepaid expenses and other current assets	499,133	435,938
Total current assets	1,761,169	9,640,738
Fixed assets, net	1,521,380	946,180
Total assets	3,282,549	10,586,918
Current liabilities:
Accounts payable	1,700,383	632,538
Accrued liabilities	1,143,863	966,899
Supplier financings	48,880	42,369
Current portion of equipment financings	255,605	110,924
Current portion of credit facility	1,896,718	1,588,058
Total current liabilities	5,045,449	3,340,788
Non-current portion of equipment financings, net	572,096	291,189
Non-current portion of credit facility, net	1,593,220	2,638,487
Non-current portion of interest payable	209,914	153,547
Non-current portion of deferred rent	418,028	470,172
Total liabilities	7,838,707	6,894,183
Commitments and contingencies (see Note 11)
Shareholders’ equity/(deficit):
Common stock, $0.0001 par value, 40,000,000 authorized; 6,556,685 issued and outstanding at December 31, 2015; 150,000,000 authorized; 8,399,397 issued and outstanding at September 30, 2016.	840	656
Additional paid-in capital	164,891,998	158,928,627
Accumulated deficit	(169,448,996)	(155,236,548)
Total shareholders’ equity/(deficit)	(4,556,158)	3,692,735
Total liabilities and shareholders’ equity/(deficit)	$ 3,282,549	$ 10,586,918

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	40,000,000
Common stock, shares issued	8,399,397	6,556,685
Common stock, shares outstanding	8,399,397	6,556,685

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Revenues:	$ 1,047,280	$ 164,856	$ 1,931,509	$ 391,626
Costs and expenses:
Cost of revenues	1,876,288	1,159,710	5,020,649	3,320,467
Research and development expenses	600,613	677,729	2,044,968	2,073,391
General and administrative expenses	1,919,843	1,630,608	4,924,731	4,281,883
Sales and marketing expenses	1,278,455	1,055,653	3,875,063	2,616,218
Total costs and expenses	5,675,199	4,523,700	15,865,411	12,291,959
Loss from operations	(4,627,919)	(4,358,844)	(13,933,902)	(11,900,333)
Other income/(expense):
Interest expense, net	(154,869)	(175,562)	(393,029)	(494,235)
Other income	38,412	38,412	115,236	64,020
Gain on sale of fixed assets	1,300		1,300
Total other income/(expense):	(115,157)	(137,150)	(276,493)	(430,215)
Loss before income taxes	(4,743,076)	(4,495,994)	(14,210,395)	(12,330,548)
Income tax expense		(199)	(2,053)	(1,478)
Net loss and comprehensive loss	$ (4,743,076)	$ (4,496,193)	$ (14,212,448)	$ (12,332,026)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	8,370,691	6,242,604	7,549,663	5,245,303
Diluted	8,370,691	6,242,604	7,549,663	5,245,303
Net loss per common share:
Basic	$ (0.57)	$ (0.72)	$ (1.88)	$ (2.35)
Diluted	$ (0.57)	$ (0.72)	$ (1.88)	$ (2.35)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows from Operating Activities:
Net loss	$ (14,212,448)	$ (12,332,026)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	248,164	188,120
Inventory reserve	(40,708)	(20,277)
Stock-based compensation	1,164,979	1,016,266
Non-cash interest expense related to credit facility and other financing activities	60,951	93,454
Gain on sale of fixed assets	(1,300)
Increase/(decrease) in cash resulting from changes in:
Accounts receivable	(51,464)	(29,760)
Inventories	(107,538)	(93,000)
Prepaid expenses and other current assets	501,532	(181,284)
Accounts payable	991,846	142,028
Accrued liabilities	152,860	218,468
Accrued interest	58,684	96,295
Deferred rent	(22,839)	5,614
Net cash used in operating activities	(11,257,281)	(10,896,102)
Cash Flows from Investing Activities:
Proceeds from sale of fixed assets	1,300
Purchases of fixed assets	(392,496)	(118,896)
Net cash used in investing activities	(391,196)	(118,896)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants	4,798,576	8,830,057
Proceeds from exercise of common stock warrants		9,697,660
Payments on equipment financings	(86,336)	(54,007)
Payments on supplier and other third party financings	(427,934)	(33,674)
Payments on line of credit	(778,303)	(247,701)
Net cash provided by financing activities	3,506,003	18,192,335
Net increase (decrease) in Cash and Cash Equivalents	(8,142,474)	7,177,337
Cash and Cash Equivalents at Beginning of Period	8,821,329	5,364,582
Cash and Cash Equivalents at End of Period	678,855	12,541,919
Cash paid during the period for:
Interest	282,142	309,324
Taxes	$ 2,053	$ 2,054

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)			9 Months Ended		12 Months Ended
	Sep. 30, 2016	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Warrants to purchase common stock, period			5 years
Purchase of common stock by underwriters to cover overallotments, grant date fair value			$ 7,700,000
Overallotment issued to underwriter to purchase common stock, period			45 days
Common shares issuable to underwriters under granted option			400,000
Purchase of common stock by underwriters to cover overallotments, per share	$ 3.75		$ 3.75
Common Shares issuable to underwriters under warrants granted			400,000
Common stock, par value	$ 0.0001		$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value			$ 1,600,000
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs		$ 63,111
Fixed assets purchased under capital lease obligations			631,232	$ 279,008
Fixed assets with a remaining net book value under capital lease obligations			126,811
Purchases of fixed assets			8,637	3,190	$ 64,300	$ 19,546
Financed insurance premium through third party financing			$ 434,475
Proceeds from exercise of common stock warrants				$ 9,697,660
Roth Capital Partners, LLC and Feltl [Member]
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs	$ 130,252
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs paid net	$ 0
Overallotment Options [Member]
Common stock, par value	$ 0.0003		$ 0.0003

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock, which was not affected by the one-for-three reverse stock split. The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended September 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern Uncertainty	9 Months Ended
Liquidity and Going Concern Uncertainty	Sep. 30, 2016
Accounting Policies [Abstract]
Liquidity and Going Concern Uncertainty	2. Liquidity and Going Concern Uncertainty As of September 30, 2016, cash and cash equivalents totaled $0.7 million and the Company had an accumulated deficit of $169.4 million. For the year and nine month periods ended December 31, 2015 and September 30, 2016, the Company incurred net losses of $16.9 million and $14.2 million, respectively. At September 30, 2016, the Company had aggregate gross interest-bearing indebtedness of approximately $5.3 million, of which approximately $2.2 million was due within one year in the absence of subjective acceleration of amounts due under a credit facility entered into in April 2014 with Oxford Finance LLC, or the April 2014 Credit Facility, in addition to approximately $2.8 million of other non-interest bearing liabilities. Additionally, in February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly installments of $62,500 through May 2020 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. Subsequent to the closing of a follow-on public offering on February 13, 2015, cash proceeds of approximately $9.8 million have been received by the Company from the exercise of warrants sold in such offering, while approximately $2.7 million in gross warrant proceeds remain outstanding and available to be exercised at $4.68 per share until their expiration in February 2020. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. A public offering of the Company’s common stock and warrants to purchase its common stock was effected under this shelf registration statement on April 29, 2016, the closing of which occurred on May 4, 2016, pursuant to which the Company received net cash proceeds of approximately $4.3 million (see Note 3). Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million (see Note 13). Management’s Plan to Continue as a Going Concern In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Sales of Equity Securities	9 Months Ended
Sales of Equity Securities	Sep. 30, 2016
Equity [Abstract]
Sales of Equity Securities Disclosure [Text Block]	3. Sales of Equity Securities Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis Capital Corp. and Feltl and Company, Inc., as underwriters named therein, a public offering of 2,666,666 shares of the Company’s common stock and warrants to purchase up to an aggregate of 2,666,666 shares of common stock was effected at a combined offering price of $3.75. The estimated grant date fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering. All warrants sold in this offering have a per share exercise price of $4.68, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on February 13, 2015, when the Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $9.1 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was $8.8 million after deducting $0.3 million of additional non-underwriter costs incurred. Additionally, the underwriters were granted a 45-day option to purchase up to 400,000 additional shares of common stock at a price of $3.75 per share and/or additional warrants to purchase up to 400,000 shares of common stock at a price of $0.0003 per warrant, less underwriting discounts and commissions, to cover overallotments, if any, which was not exercised. The estimated grant date fair value of the overallotment options and warrants of $1.6 million was recorded as an offset to additional paid-in capital within common stock issuance costs upon the closing of this offering. Underwriter costs and discounts of $0.2 million and $0.7 million, respectively, as well as additional non-underwriter costs associated with this offering of $0.3 million, were also recorded to common stock issuance costs upon closing. Subsequent to the closing of this offering on February 13, 2015, additional cash proceeds of $9.8 million have been received from the exercise of warrants sold in such offering. As such, the aggregate total increase in capital related to this offering has been $18.6 million, after deducting the $0.9 million of underwriter costs and discounts and $0.3 million of additional non-underwriter costs incurred, which were offset against these proceeds under applicable accounting guidance. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as the Company’s public float is less than $75 million. Pursuant to an exclusive placement agent agreement dated April 25, 2016 between the Company and H.C. Wainwright & Co., LLC, or Wainwright, and a securities purchase agreement dated April 29, 2016 between the Company and the purchasers signatory thereto, a public offering of 1,662,191 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,163,526 shares of common stock was effected under this registration statement at a combined offering price of $3.00. All warrants sold in this offering have a per share exercise price of $3.90, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the purchasers occurred on May 4, 2016, pursuant to which the Company received, after deducting the placement agent’s fees and non-accountable expense reimbursements paid to Wainwright, as well as advisory service fees paid to Roth Capital Partners, LLC and certain other transactional fees paid to third parties, approximately $4.6 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants was approximately $4.3 million after deducting an estimated $0.3 million of additional third party costs incurred in connection with this offering. An aggregate balance of approximately $0.7 million related to placement agent’s fees, advisory service expenses and non-placement agent costs associated with this offering was recorded to common stock issuance costs upon closing under applicable accounting guidance. Subsequent to the closing of this public offering on May 4, 2016, no warrants sold in such offering have been exercised, with approximately $4.5 million in gross warrant proceeds remaining outstanding and available to be exercised at $3.90 per share until their expiration in May 2021. Following this offering and through the date that the Company’s September 30, 2016 unaudited condensed financial statements are available to be issued, given the limitations that apply for so long as the Company’s public float is less than $75 million, no additional common stock, preferred stock, debt securities or warrants may be sold by the Company under this shelf registration statement. In connection with its public offering in May 2016, the Company has agreed to certain contractual terms that limit its ability to issue variable rate securities for a period of one year. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. On December 21, 2015, the Company entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire Capital, which committed to purchase up to an aggregate of $15.0 million of shares of the Company’s common stock over the 30-month term of the common stock purchase agreement. On November 4, 2016, the Company voluntarily terminated this common stock purchase agreement (see Note 13). Upon execution of the common stock purchase agreement, the Company sold to Aspire Capital 208,334 shares of common stock at $4.80 per share for proceeds of $1,000,000, and concurrently also entered into a registration rights agreement with Aspire Capital, pursuant to which the Company filed a registration statement registering the sale of the shares of the Company’s common stock that were issued to Aspire Capital under the common stock purchase agreement. Under the common stock purchase agreement, on any trading day selected by the Company, the Company had the right, in its sole discretion, to present a purchase notice directing Aspire Capital to purchase up to 33,333 shares of the Company’s common stock per business day, up to $15.0 million of common stock in the aggregate at a per share price equal to the lesser of either (i) the lowest sale price of the Company’s common stock on the purchase date, or (ii) the arithmetic average of the three lowest closing sale prices for the Company’s common stock during the 10 consecutive trading days ending on the trading day immediately preceding the purchase date. In addition, on any date on which the Company submitted a purchase notice to Aspire Capital in an amount equal to 33,333 shares and the Company’s stock price was not less than $1.50 per share, the Company also had the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of the Company’s common stock traded on the its principal market on the next trading day, subject to a maximum number of shares the Company could determine. The purchase price per share pursuant to such volume-weighted average price purchase notice was generally 97% of the volume-weighted average price for the Company’s common stock traded on its principal market on the volume-weighted average purchase date. The purchase price was to be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction occurring during the period(s) used to compute the purchase price. The Company could have delivered multiple purchase notices and volume-weighted average price purchase notices to Aspire Capital from time to time during the term of the common stock purchase agreement, so long as the most recent purchase had been completed. The common stock purchase agreement provided that the Company and Aspire Capital would not effect any sales on any purchase date where the closing sale price of the Company’s common stock was less than $1.50. There were no trading volume requirements or restrictions under the common stock purchase agreement, and the Company controlled the timing and amount of sales of its common stock to Aspire Capital. Aspire Capital had no right to require any sales by the Company, but was obligated to make purchases from the Company as directed by the Company in accordance with the common stock purchase agreement. There were no limitations on use of proceeds, financial or business covenants, restrictions on future fundings, rights of first refusal, participation rights, penalties or liquidated damages in the common stock purchase agreement. In consideration for entering into, and concurrently with the execution of, the common stock purchase agreement, the Company issued to Aspire Capital 55,000 shares of its common stock. The common stock purchase agreement could have been terminated by the Company at any time, at its discretion, without any cost to the Company. Aspire Capital had agreed that neither it nor any of its agents, representatives and affiliates were to engage in any direct or indirect short-selling or hedging of the Company’s common stock during any time prior to the termination of the common stock purchase agreement. The proceeds received by the Company under the common stock purchase agreement were used for working capital and general corporate purposes. During the nine months ended September 30, 2016, the Company submitted purchase notices to Aspire Capital for an aggregate of 173,145 shares of common stock for gross proceeds of $544,051. Costs associated with this offering of approximately $42,000 and $83,000 during the year ended December 31, 2015 and nine months ended September 30, 2016, respectively, were also recorded to common stock issuance costs under applicable accounting guidance, and as such, the aggregate total increase in capital related to this transaction was approximately $1.4 million. Pursuant to an underwriting agreement dated October 14, 2016 between the Company, Roth Capital Partners, LLC and Feltl and Company, Inc., as underwriters named therein, a public offering of 9,100,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 9,100,000 shares of common stock was effected at a combined offering price of $1.10 for total gross proceeds to the Company of approximately $10.0 million (see Note 13).

XML 21 R10.htm IDEA: XBRL DOCUMENT

Fair Value Measurement

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurement

4. Fair Value Measurement

Other Fair Value Measurements

Stock price	$	2.70
Exercise price	$	3.90
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.23	%
Expected life (in years)		5.00
Expected volatility		90.0	%

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Balance Sheet Details

9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Details

5. Balance Sheet Details

The following provides certain balance sheet details:

	December 31,		September 30,
	2015		2016
Fixed Assets
Machinery and equipment	$	2,518,158	$	2,707,601
Furniture and office equipment		143,726		143,726
Computer equipment and software		577,898		617,802
Leasehold improvements		514,614		517,968
Financed equipment		914,179		1,457,377
Construction in process		70,815		118,280
		4,739,390		5,562,754
Less accumulated depreciation and amortization		3,793,210		4,041,374
Total fixed assets, net	$	946,180	$	1,521,380
Accrued Liabilities
Accrued interest	$	28,981	$	23,825
Accrued payroll		128,753		301,988
Accrued vacation		307,845		313,825
Accrued bonuses		376,100		318,237
Accrued sales commissions		76,574		97,844
Current portion of deferred rent		31,170		60,475
Accrued other		17,476		27,669
Total accrued liabilities	$	966,899	$	1,143,863

XML 23 R12.htm IDEA: XBRL DOCUMENT

April 2014 Credit Facility	9 Months Ended
April 2014 Credit Facility	Sep. 30, 2016
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility with Oxford Finance LLC. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Amounts due to Oxford Finance LLC under the April 2014 Credit Facility are callable before maturity by the lender under certain subjective acceleration clauses of the underlying agreement, including changes deemed to be materially adverse by the lender. The term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the term loan, plus (b) 7.71%. The term loan bears interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matures on July 1, 2018. Under the original terms of the underlying agreement, the Company is also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loan in whole but not in part, subject to a prepayment fee of 1% of any amount prepaid. On June 30, 2016, the Company entered into an amendment of the April 2014 Credit Facility. This amendment required the Company to make interest-only payments on the term loan from July 1, 2016 through September 30, 2016, and also requires an additional final payment of $50,000 to the lender. If on or before September 30, 2016 the Company received unrestricted net cash proceeds of at least $7.0 million from the issuance and sale its equity securities, or the Company received a signed letter of intent relating to a sale or merger of the Company, in form and substance satisfactory to the lender, the Company could have been required to make interest-only payments on the term loan through December 31, 2016, and the amount of the additional final payment to the lender upon repayment would have increased to $75,000, which did not occur. The terms of the amendment require the amortization of the outstanding amount due under the term loan to commence at the end of the applicable interest-only period, with monthly payments of principal and interest, in arrears, being made by the Company to the lender in consecutive monthly installments following such interest-only period. Additionally, pursuant to the amendment the aggregate outstanding principal amount of the Company’s permitted indebtedness, consisting of capitalized lease obligations and purchase money indebtedness outstanding at any time, was increased to $1.2 million. The June 30, 2016 amendment of the Company’s 2014 Credit Facility was accounted for as a modification of debt under applicable accounting guidance. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries created in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loan under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including its cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000. A warrant to purchase up to 17,655 shares of the Company’s common stock at an exercise price of $14.16 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of $102,498 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,897,502. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The effective annual interest rate associated with the April 2014 Credit Facility was 11.50% and 13.87% at December 31, 2015 and September 30, 2016, respectively.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Capital Lease Obligations

9 Months Ended

Sep. 30, 2016

Capital Lease Obligations [Abstract]

Capital Lease Obligations

7. Capital Lease Obligations

	Minimum		Maintenance
	Lease		Obligation
	Payments		Payments
2016	$	68,754	$	6,375
2017		238,287		25,440
2018		190,333		25,434
2019		155,388		24,676
2020		151,400		24,608
Thereafter		374,005		59,471
Total payments		1,178,167		166,004
Less amount representing interest		350,466		—
Present value of payments	$	827,701	$	166,004

At September 30, 2016, the present value of minimum lease payments due within one year was $255,605.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation

8. Stock-based Compensation

Equity Incentive Plans

The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. On July 25, 2016, the Company’s Board of Directors approved an amendment to the 2013 Plan to reserve 1,000,000 shares on a pre-reverse stock split basis, or 333,333 shares on a post-reverse stock split basis, of the Company’s common stock exclusively for the grant of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. In conjunction with the one-for-three reverse split of the Company’s common stock effected on September 27, 2016, the number of non-inducement shares authorized under all plans decreased from 3,068,865 to 1,022,955 shares, and the number of inducement shares authorized under the 2013 Plan decreased from 1,000,000 shares to 333,333 shares. As of September 30, 2016, under all plans, a total of 1,022,955 non-inducement shares were authorized for issuance, 978,358 non-inducement stock options and restricted stock units, or RSUs, had been issued and were outstanding, and 3,115 non-inducement shares were available for grant. As of September 30, 2016, a total of 333,333 inducement shares were authorized for issuance, 124,999 inducement stock options and RSUs had been issued and were outstanding, and 208,334 inducement shares were available for grant under the 2013 Plan.

Stock Options

A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Vested and unvested expected to vest, December 31, 2015		646,900		$	15.48		9.0
Outstanding at December 31, 2015		713,659		$	11.23		9.0
Granted		276,628		$	2.60
Exercised		—
Cancelled/forfeited/expired		(63,679	)	$	8.08
Outstanding at September 30, 2016		926,608		$	8.87		8.7
Vested and unvested expected to vest, September 30, 2016		838,037		$	9.37		8.1

The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:

Stock and exercise prices	$1.57 - $4.02
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield	0.99% – 1.39%
Expected life (in years)	5.13 – 6.08
Expected volatility	80.0% - 90.0%

	Percentage of
	Overall Stock
	Option Grants
	Subject to Vesting
Target
Minimum number of accessions processed, billed and collected		13	%
Minimum revenues from contracts with pharmaceutical companies		10	%
Attainment of a sustainable positive GAAP gross margin		12	%
Minimum operating cash on-hand with no more than one interim dilutive equity financing event		15	%
Achievement of the Company's 2016 corporate goals		25	%
Completion of a Board-approved strategic transaction		25	%
Total		100	%

Restricted Stock

A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

				Weighted
	Number of			Average Grant
	Shares			Date Fair Value
Vested and unvested expected to vest, December 31, 2015		15,369		$	14.49
Outstanding at December 31, 2015		25,752		$	15.12
Granted		165,829		$	1.96
Vested and issued		(4,449	)	$	16.05
Forfeited		(10,383	)	$	16.05
Outstanding at September 30, 2016		176,749		$	2.70
Vested and unvested expected to vest, September 30, 2016		172,550		$	2.71

	Percentage of
	Overall RSU
	Grant Subject to
	Vesting
Target
Minimum revenue		25	%
Maximum EBITDA loss		15	%
Attainment of financial plan for fiscal 2015		20	%
Minimum value of strategic agreements		20	%
Implementation of four new diagnostic test panels		20	%
Total		100	%

Stock-based Compensation Expense

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2015		2016		2015		2016
Stock Options
Cost of revenues	$	15,029	$	34,119	$	48,839	$	89,606
Research and development expenses		20,910		28,189		65,835		87,153
General and administrative expenses		257,404		292,381		706,026		829,516
Sales and marketing expenses		31,888		51,924		93,989		91,164
Total expenses related to stock options		325,231		406,613		914,689		1,097,439
RSUs
Cost of revenues		—		14,918		—		16,834
Research and development expenses		1,625		14,131		10,724		15,583
General and administrative expenses		12,515		6,668		90,853		7,676
Sales and marketing expenses		—		22,939		—		27,447
Total stock-based compensation	$	339,371	$	465,269	$	1,016,266	$	1,164,979

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 26 R15.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding

9 Months Ended

Sep. 30, 2016

Other Liabilities Disclosure [Abstract]

Common Stock Warrants Outstanding

9. Common Stock Warrants Outstanding

A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2016 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2015		784,234		$	11.19		3.8
Issued		1,163,526		$	3.90
Exercised		—
Expired		(50,904	)	$	30.00
Outstanding at September 30, 2016		1,896,856		$	6.21		4.1

The intrinsic value of equity-classified common stock warrants outstanding and exercisable at September 30, 2016 was zero.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Loss per Common Share

10. Net Loss per Common Share

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and nine months ended
	September 30,
	2015		2016
Preferred warrants outstanding (number of common stock equivalents)		529		529
Preferred share RSUs (number of common stock equivalents)		24,384		—
Common warrants outstanding		797,579		1,896,856
Common share RSUs		25,752		176,749
Common options outstanding		684,779		926,608
Total anti-dilutive common share equivalents		1,533,023		3,000,742

XML 28 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. In February 2016, the Company signed a firm, noncancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in quarterly installments of $62,500 through May 2020.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 47,331 shares of the Company’s common stock and warrants to purchase up to an aggregate of 47,331 shares of its common stock for total gross proceeds of $177,500 (see Note 3). A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received a payment of $19,047 during the nine months ended September 30, 2016 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement. Pursuant to a sublease agreement dated March 30, 2015, the Company subleased 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A total of $64,020 and $115,236 in rental income was recorded to other income in the Company’s unaudited condensed statements of operations and comprehensive loss during the nine months ended September 30, 2015 and 2016, respectively. Three members of the Company’s Board of Directors participated in its public offering in May 2016, purchasing an aggregate of 58,335 shares of the Company’s common stock and warrants to purchase up to an aggregate of 40,832 shares of its common stock for total gross proceeds to the Company of $175,000. Additionally, a trust affiliated with the Company’s major stockholder, Claire K.T. Reiss, participated in its public offering in May 2016, purchasing 204,758 shares of its common stock and warrants to purchase up to 143,330 shares of its common stock for total gross proceeds to the Company of $614,273 (see Note 3). The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

13. Subsequent Events

	Overallotment Options			Warrants
Stock price	$	0.93		$	0.93
Exercise price	$	1.0331		$	1.10
Expected dividend yield		0.00	%		0.00	%
Discount rate-bond equivalent yield		0.25	%		1.24	%
Expected life (in years)		0.08			5.00
Expected volatility		12.9	%		80.0	%

Over the past several years the Company has generated operating losses in all jurisdictions in which it may be subject to income taxes. As a result, the Company has accumulated significant net operating losses and other deferred tax assets. Because of the Company’s history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized. The Company does not expect to report a provision for income taxes until it has a history of earnings, if ever, that would support the realization of its deferred tax assets.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles, or GAAP, to be included in a full set of financial statements. The balance sheet at December 31, 2015 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2015, filed with the SEC with our Annual Report on Form 10-K on March 10, 2016 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares. As such, all references to share and per share amounts in the unaudited condensed financial statements and accompanying notes to the unaudited condensed financial statements have been retroactively restated to reflect the one-for-three reverse stock split, except for the authorized number of shares of the Company’s common stock, which was not affected by the one-for-three reverse stock split.
The Company and Business Activities	The Company and Business Activities Biocept, Inc., or the Company, was founded in California in May 1997 and is an early stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, and as subsequently updated and amended from time to time, the Financial Accounting Standards Board, or FASB, issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company adopted this guidance for the interim reporting period ended September 30, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In July 2015, the FASB issued authoritative guidance requiring entities that do not measure inventory using the retail inventory method or on a last-in, first-out basis to record inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective on a prospective basis for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In January 2016, the FASB issued authoritative guidance requiring, among other things, that certain equity investments be measured at fair value with changes in fair value recognized in net income, that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements, that the prior requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet be eliminated, and that a reporting organization is to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the organization has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption of the instrument-specific credit risk amendment is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In February 2016, the FASB issued authoritative guidance requiring, among other things, that entities recognize the assets and liabilities arising from leases on the balance sheet under revised criteria, while the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria in the previous leases guidance. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance clarifying that a change in the counterparty to a derivative instrument that has been designated as the hedging instrument does not necessarily require dedesignation of that hedging relationship, provided that all other applicable hedge accounting criteria continue to be met. This guidance is effective on either a prospective basis or modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance requiring entities to assess whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, and clarifies what steps are required when assessing whether the economic characteristics and risks of call (put) options are clearly and closely related to the economic characteristics and risks of their debt hosts. This guidance is effective on a modified retrospective basis for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In March 2016, the FASB issued authoritative guidance simplifying the accounting for stock compensation. This guidance, among other things, amends existing accounting and classification requirements primarily around income taxes, forfeitures, and cash payments associated with share-based payment awards to employees. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In August 2016, the FASB issued authoritative guidance clarifying the classification of certain cash receipts and cash payments in the statement of cash flows. This guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
Fair Value Measurement	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurement (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Assumptions Used for Determining Fair Values of Common Stock Warrants

the estimated grant date fair value of $1.72 per share associated with the warrants to purchase 1,163,526 shares of common stock issued in such offering, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in capital within common stock issuance costs, and was estimated using a Black-Scholes valuation model with the following assumptions:

Stock price	$	2.70
Exercise price	$	3.90
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.23	%
Expected life (in years)		5.00
Expected volatility		90.0	%

XML 33 R22.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Tables)

9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Fixed Assets and Accrued Liabilities

The following provides certain balance sheet details:

	December 31,		September 30,
	2015		2016
Fixed Assets
Machinery and equipment	$	2,518,158	$	2,707,601
Furniture and office equipment		143,726		143,726
Computer equipment and software		577,898		617,802
Leasehold improvements		514,614		517,968
Financed equipment		914,179		1,457,377
Construction in process		70,815		118,280
		4,739,390		5,562,754
Less accumulated depreciation and amortization		3,793,210		4,041,374
Total fixed assets, net	$	946,180	$	1,521,380
Accrued Liabilities
Accrued interest	$	28,981	$	23,825
Accrued payroll		128,753		301,988
Accrued vacation		307,845		313,825
Accrued bonuses		376,100		318,237
Accrued sales commissions		76,574		97,844
Current portion of deferred rent		31,170		60,475
Accrued other		17,476		27,669
Total accrued liabilities	$	966,899	$	1,143,863

XML 34 R23.htm IDEA: XBRL DOCUMENT

Capital Lease Obligations (Tables)

9 Months Ended

Sep. 30, 2016

Capital Lease Obligations [Abstract]

Schedule of Future Minimum Lease Payments for Capital Lease Obligations

	Minimum		Maintenance
	Lease		Obligation
	Payments		Payments
2016	$	68,754	$	6,375
2017		238,287		25,440
2018		190,333		25,434
2019		155,388		24,676
2020		151,400		24,608
Thereafter		374,005		59,471
Total payments		1,178,167		166,004
Less amount representing interest		350,466		—
Present value of payments	$	827,701	$	166,004

XML 35 R24.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity for Option Awards Granted

A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Vested and unvested expected to vest, December 31, 2015		646,900		$	15.48		9.0
Outstanding at December 31, 2015		713,659		$	11.23		9.0
Granted		276,628		$	2.60
Exercised		—
Cancelled/forfeited/expired		(63,679	)	$	8.08
Outstanding at September 30, 2016		926,608		$	8.87		8.7
Vested and unvested expected to vest, September 30, 2016		838,037		$	9.37		8.1

Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model

The fair values of option awards granted during the nine months ended September 30, 2016 were estimated using a Black-Scholes pricing model with the following assumptions:

Stock and exercise prices	$1.57 - $4.02
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield	0.99% – 1.39%
Expected life (in years)	5.13 – 6.08
Expected volatility	80.0% - 90.0%

Schedule of Performance Stock Options Vesting Percentage

Vesting of these stock options may occur based on the Company’s achievement of specified objectives by December 31, 2016 as determined by the Company’s Board of Directors, or a committee of the Company’s Board of Directors, in its sole discretion, as follows:

	Percentage of
	Overall Stock
	Option Grants
	Subject to Vesting
Target
Minimum number of accessions processed, billed and collected		13	%
Minimum revenues from contracts with pharmaceutical companies		10	%
Attainment of a sustainable positive GAAP gross margin		12	%
Minimum operating cash on-hand with no more than one interim dilutive equity financing event		15	%
Achievement of the Company's 2016 corporate goals		25	%
Completion of a Board-approved strategic transaction		25	%
Total		100	%

Vesting of these RSUs was based on the Company’s achievement of specified objectives by December 31, 2015 as determined by the Company’s Board of Directors or the Compensation Committee of the Board of Directors, as follows:

	Percentage of
	Overall RSU
	Grant Subject to
	Vesting
Target
Minimum revenue		25	%
Maximum EBITDA loss		15	%
Attainment of financial plan for fiscal 2015		20	%
Minimum value of strategic agreements		20	%
Implementation of four new diagnostic test panels		20	%
Total		100	%

Summary of RSU Activity for Awards Granted

A summary of RSU activity for awards granted under the 2013 Plan and 2007 Plan for the nine months ended September 30, 2016 is as follows:

				Weighted
	Number of			Average Grant
	Shares			Date Fair Value
Vested and unvested expected to vest, December 31, 2015		15,369		$	14.49
Outstanding at December 31, 2015		25,752		$	15.12
Granted		165,829		$	1.96
Vested and issued		(4,449	)	$	16.05
Forfeited		(10,383	)	$	16.05
Outstanding at September 30, 2016		176,749		$	2.70
Vested and unvested expected to vest, September 30, 2016		172,550		$	2.71

Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2015		2016		2015		2016
Stock Options
Cost of revenues	$	15,029	$	34,119	$	48,839	$	89,606
Research and development expenses		20,910		28,189		65,835		87,153
General and administrative expenses		257,404		292,381		706,026		829,516
Sales and marketing expenses		31,888		51,924		93,989		91,164
Total expenses related to stock options		325,231		406,613		914,689		1,097,439
RSUs
Cost of revenues		—		14,918		—		16,834
Research and development expenses		1,625		14,131		10,724		15,583
General and administrative expenses		12,515		6,668		90,853		7,676
Sales and marketing expenses		—		22,939		—		27,447
Total stock-based compensation	$	339,371	$	465,269	$	1,016,266	$	1,164,979

XML 36 R25.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding (Tables)

9 Months Ended

Sep. 30, 2016

Equity Classified Warrants [Abstract]

Summary of Equity-Classified Common Stock Warrant Activity

A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2016 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2015		784,234		$	11.19		3.8
Issued		1,163,526		$	3.90
Exercised		—
Expired		(50,904	)	$	30.00
Outstanding at September 30, 2016		1,896,856		$	6.21		4.1

XML 37 R26.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and nine months ended
	September 30,
	2015		2016
Preferred warrants outstanding (number of common stock equivalents)		529		529
Preferred share RSUs (number of common stock equivalents)		24,384		—
Common warrants outstanding		797,579		1,896,856
Common share RSUs		25,752		176,749
Common options outstanding		684,779		926,608
Total anti-dilutive common share equivalents		1,533,023		3,000,742

XML 38 R27.htm IDEA: XBRL DOCUMENT

Subsequent Events (Tables)

9 Months Ended

Sep. 30, 2016

Assumptions Used for Determining Fair Values of Common Stock Warrants

Stock price	$	2.70
Exercise price	$	3.90
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		1.23	%
Expected life (in years)		5.00
Expected volatility		90.0	%

Overallotment Options, Overallotment Warrants and Non-overallotment Warrants [Member]

Assumptions Used for Determining Fair Values of Common Stock Warrants

The fair values of these overallotment options and all warrants issued in the October 2016 offering were estimated using Black-Scholes valuation models with the following assumptions:

	Overallotment Options			Warrants
Stock price	$	0.93		$	0.93
Exercise price	$	1.0331		$	1.10
Expected dividend yield		0.00	%		0.00	%
Discount rate-bond equivalent yield		0.25	%		1.24	%
Expected life (in years)		0.08			5.00
Expected volatility		12.9	%		80.0	%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation - Additional Information (Detail)		9 Months Ended
Basis of Presentation - Additional Information (Detail)	Sep. 27, 2016 shares	Sep. 30, 2016 shares	Dec. 31, 2015 shares
Summary Of Significant Accounting Policies [Line Items]
Stockholders equity reverse stock split ratio	0.33
Common stock, shares authorized		150,000,000	40,000,000
Description of reverse stock split		On September 27, 2016, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s amended and restated certificate of incorporation to effect a one-for-three reverse stock split of the Company’s outstanding common stock, and to increase the authorized number of shares of the Company’s common stock from 40,000,000 to 150,000,000 shares.
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized	40,000,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares authorized	150,000,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)					1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Feb. 13, 2015	Nov. 09, 2016	May 31, 2016	Feb. 29, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	May 31, 2015	Dec. 31, 2014
Liquidity And Managements Plans [Line Items]
Cash and cash equivalents								$ 678,855	$ 12,541,919	$ 678,855	$ 12,541,919	$ 8,821,329		$ 5,364,582
Accumulated deficit								(169,448,996)		(169,448,996)		(155,236,548)
Net loss								(4,743,076)	$ (4,496,193)	(14,212,448)	(12,332,026)	$ (16,900,000)
Other non-interest bearing liabilities								$ 2,800,000		$ 2,800,000
Unconditional purchase commitment aggregate amount							$ 1,062,500
Unconditional purchase commitment, quarterly payment amount							62,500
Unconditional purchase commitment payment terms										Quarterly
Unconditional purchase commitment period										May 31, 2020
Proceeds from exercise of common stock warrants				$ 9,800,000							$ 9,697,660
Proceeds from gross exercise of common stock warrants outstanding				$ 2,700,000
Exercisable warrant available price per share				$ 4.68
Exercisable warrant available price per share expiration period				2020-02
Issuance of warrants to purchase shares of common stock			1,163,526	400,000
Stock price								$ 2.70		$ 2.70
Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants	$ 564	$ 564			$ 0
Roth Capital Partners, LLC and Feltl [Member] \| Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Public offering, number of shares issued		9,100,000
Issuance of warrants to purchase shares of common stock	9,100,000	9,100,000
Stock price		$ 1.10
Proceeds from issuance of common stock		$ 10,000,000
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants			$ 0
Proceeds from gross exercise of common stock warrants outstanding			$ 4,500,000
Exercisable warrant available price per share			$ 3.90
Exercisable warrant available price per share expiration period			2021-05
Minimum public float limit for offering			$ 75,000,000			$ 75,000,000							$ 75,000,000
Proceeds from issuance of common stock, net of issuance costs			$ 4,300,000
Period of limitation to issue variable rate securities			1 year			1 year
Issuance of warrants to purchase shares of common stock			1,163,526
Stock price			$ 3.00
Proceeds from issuance of common stock			$ 4,600,000
April 2014 Credit Facility [Member]
Liquidity And Managements Plans [Line Items]
Aggregate gross interest-bearing indebtedness								$ 5,300,000		$ 5,300,000
Due within one year								$ 2,200,000		$ 2,200,000
Minimum [Member]
Liquidity And Managements Plans [Line Items]
Unconditional purchase commitment, quarterly payment amount							$ 62,500
Maximum [Member] \| Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock	1,365,000	1,365,000
Maximum [Member] \| Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price													$ 50,000,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Sales of Equity Securities - Additional Information (Detail) - USD ($)							1 Months Ended		9 Months Ended		12 Months Ended
	Oct. 19, 2016	Oct. 14, 2016	May 04, 2016	Dec. 21, 2015	Feb. 13, 2015	Feb. 09, 2015	Nov. 09, 2016	May 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	May 31, 2015
Class Of Stock [Line Items]
Stock price									$ 2.70
Purchase of common stock by underwriters to cover overallotments, grant date fair value			$ 2,000,000						$ 7,700,000
Exercise price of warrants			$ 3.90		$ 4.68
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs					$ 9,100,000
Increase in capital shares value						$ 8,800,000			$ 1,400,000
Additional costs incurred prior to, and associated with IPO, beginning of period					$ 300,000
Overallotment issued to underwriter to purchase common stock, period						45 days			45 days
Purchase of common stock by underwriters to cover overallotments, number of shares					400,000
Issuance of warrants to purchase shares of common stock			1,163,526		400,000
Purchase of common stock by underwriters to cover overallotments, per share					$ 3.75				$ 3.75
Common stock, par value					$ 0.0003				$ 0.0001		$ 0.0001
Issuance of warrants to purchase shares of common stock, grant date fair value					$ 1,600,000				$ 1,600,000
Underwriter cost					200,000
Underwriting discounts					700,000
Non-underwriter costs					300,000
Proceeds from exercise of common stock warrants					9,800,000					$ 9,697,660
Aggregate increase in capital from public offerings					18,600,000
Underwriting cost and discount					$ 900,000
Common stock issuance costs									$ 83,000		$ 42,000
Exercisable warrant available price per share expiration period					2020-02
Common stock, shares issued									8,399,397		6,556,685
Subsequent Event [Member]
Class Of Stock [Line Items]
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 5,200,000	$ 5,200,000
Exercise price of warrants	$ 1.10	$ 1.10
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs	$ 9,400,000
Overallotment issued to underwriter to purchase common stock, period	30 days	30 days
Purchase of common stock by underwriters to cover overallotments, number of shares	627,131	627,131
Purchase of common stock by underwriters to cover overallotments, per share	$ 1.0331	$ 1.0331
Common stock, par value	$ 0.0009	$ 0.0009
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 800,000	$ 800,000
Underwriter cost	600,000
Non-underwriter costs		600,000
Proceeds from exercise of common stock warrants	564	$ 564					$ 0
Underwriting cost and discount	600,000
Increase in capital shares value	$ 8,800,000
Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Maximum number of shares of common stock to be purchase per business day				33,333
Aggregate amount of common stock				$ 15,000,000
Consecutive trading days threshold				10 days
Common stock shares trading volume percentage				30.00%
Percentage of volume weighted average price				97.00%
Common stock, shares issued				55,000
Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Proceeds from issuance of common stock									$ 544,051
Aggregate common stock shares purchase									173,145
Common Stock [Member] \| Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued				208,334
Stock price				$ 4.80
Increase in capital shares value				$ 15,000,000
Overallotment issued to underwriter to purchase common stock, period				30 months
Proceeds from issuance of common stock				$ 1,000,000
Maximum [Member] \| Subsequent Event [Member]
Class Of Stock [Line Items]
Purchase of common stock by underwriters to cover overallotments, number of shares	1,365,000	1,365,000
Issuance of warrants to purchase shares of common stock	1,365,000	1,365,000
Minimum [Member] \| Aspire Capital Fund, LLC [Member]
Class Of Stock [Line Items]
Stock price				$ 1.50
Sale of common stock, closing price per share				$ 1.50
Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Stock price			$ 3.00
Exercise price of warrants			$ 3.90
Issuance of warrants to purchase shares of common stock			1,163,526
Proceeds from exercise of common stock warrants			$ 0
Minimum public float limit for offering			$ 75,000,000					$ 75,000,000				$ 75,000,000
Period of limitation to issue variable rate securities			1 year					1 year
Placement agent agreement, effective date			Apr. 25, 2016
Securities purchase agreement, effective date			Apr. 29, 2016
Public offering, number of shares issued			1,662,191
Proceeds from issuance of common stock			$ 4,600,000
Increase in capital shares value			4,300,000
Third party costs incurred in connection with offering			300,000
Common stock issuance costs			700,000
Proceeds from gross exercise of common stock warrants outstanding			$ 4,500,000
Exercisable warrant available price per share expiration period			2021-05
Shelf Registration Statement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price												$ 50,000,000
Aegis Capital Corp. and Feltl [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued						2,666,666
Stock price					$ 3.75
Roth Capital Partners, LLC and Feltl [Member] \| Subsequent Event [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued		9,100,000
Stock price		$ 1.10
Issuance of warrants to purchase shares of common stock	9,100,000	9,100,000
Proceeds from issuance of common stock		$ 10,000,000

XML 42 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	May 04, 2016	Sep. 30, 2016	Feb. 13, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 2.0	$ 7.7
Issuance of warrants to purchase shares of common stock	1,163,526		400,000
Warrant exercise price		$ 3.90
Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant exercise price	$ 1.72

XML 43 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	9 Months Ended
	Sep. 30, 2016 $ / shares
Fair Value Disclosures [Abstract]
Stock price	$ 2.70
Exercise price	$ 3.90
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.23%
Expected life (in years)	5 years
Expected volatility	90.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Fixed Assets
Machinery and equipment	$ 2,707,601	$ 2,518,158
Furniture and office equipment	143,726	143,726
Computer equipment and software	617,802	577,898
Leasehold improvements	517,968	514,614
Financed equipment	1,457,377	914,179
Construction in process	118,280	70,815
Total fixed assets, gross	5,562,754	4,739,390
Less accumulated depreciation and amortization	4,041,374	3,793,210
Total fixed assets, net	1,521,380	946,180
Accrued Liabilities
Accrued interest	23,825	28,981
Accrued payroll	301,988	128,753
Accrued vacation	313,825	307,845
Accrued bonuses	318,237	376,100
Accrued sales commissions	97,844	76,574
Current portion of deferred rent	60,475	31,170
Accrued other	27,669	17,476
Total accrued liabilities	$ 1,143,863	$ 966,899

XML 45 R34.htm IDEA: XBRL DOCUMENT

April 2014 Credit Facility - Additional Information (Detail) - USD ($)					9 Months Ended	12 Months Ended
	Dec. 31, 2016	May 04, 2016	Feb. 13, 2015	Apr. 30, 2014	Sep. 30, 2016	Dec. 31, 2014	Dec. 31, 2015
Line of Credit Facility [Line Items]
Exercise price of warrants		$ 3.90	$ 4.68
Warrant term		5 years			5 years
Issuance of warrants to purchase shares of common stock, grant date fair value			$ 1,600,000		$ 1,600,000
Minimum [Member]
Line of Credit Facility [Line Items]
Unrestricted cash proceeds from Issuance of equity securities					7,000,000
Oxford Finance LLC [Member]
Line of Credit Facility [Line Items]
Additional final payment to lender					50,000
Oxford Finance LLC [Member] \| Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender				17,655
Exercise price of warrants				$ 14.16
Warrant term				10 years
Oxford Finance LLC [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Debt Default limit amount				$ 250,000
Debt default final judgment amount				250,000
Oxford Finance LLC [Member] \| First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan				4,898,000
Line Of Credit Facility Fees Amount Payable				$ 50,000
Line of Credit Facility, Interest Rate During Period				7.95%
Percentage of final interest payment due at maturity				5.50%
Total indebtedness and capital lease obligations outstanding					$ 1,200,000
Issuance costs						$ 102,498
Net proceeds from credit facility						4,897,502
Issuance of warrants to purchase shares of common stock, grant date fair value						$ 233,107
Effective annual interest rate					13.87%		11.50%
Oxford Finance LLC [Member] \| Scenario One
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period				7.95%
Oxford Finance LLC [Member] \| Scenario Two
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period				7.71%
Oxford Finance LLC [Member] \| Scenario Forecast [Member]
Line of Credit Facility [Line Items]
Additional final payment to lender	$ 75,000
Two Years [Member] \| Oxford Finance LLC [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage				1.00%

XML 46 R35.htm IDEA: XBRL DOCUMENT

Capital Lease Obligations - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Capital Lease Obligations [Line Items]
Financed equipment	$ 1,457,377		$ 1,457,377		$ 914,179
Accumulated depreciation related to leased equipment	616,000		$ 616,000		$ 523,000
Lease obligation weighted average effective annual interest rates			13.35%
Lease obligations maturity date on outstanding arrangements range, Start			2017-07
Lease obligations maturity date on outstanding arrangements range, End			2023-05
Present value of minimum lease payment due within one year	255,605		$ 255,605
Capital Lease Equipment [Member]
Capital Lease Obligations [Line Items]
Depreciation expense for the leased equipment	$ 40,000	$ 24,000	$ 93,000	$ 49,000
Minimum [Member] \| Capital Lease Equipment [Member]
Capital Lease Obligations [Line Items]
Lease equipment useful life			5 years
Maximum [Member] \| Capital Lease Equipment [Member]
Capital Lease Obligations [Line Items]
Lease equipment useful life			7 years

XML 47 R36.htm IDEA: XBRL DOCUMENT

Capital Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Lease Obligations (Detail)	Sep. 30, 2016 USD ($)
Capital Lease Obligations [Abstract]
2016	$ 68,754
2017	238,287
2018	190,333
2019	155,388
2020	151,400
Thereafter	374,005
Total payments	1,178,167
Less amount representing interest	350,466
Present value of payments	827,701
2016	6,375
2017	25,440
2018	25,434
2019	24,676
2020	24,608
Thereafter	59,471
Total payments	166,004
Present value of payments	$ 166,004

XML 48 R37.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Detail)								3 Months Ended		9 Months Ended
	Sep. 27, 2016 shares	Jul. 29, 2016 $ / shares shares	Jul. 25, 2016 $ / shares shares	Jul. 06, 2016 USD ($) $ / shares shares	Feb. 29, 2016 $ / shares shares	Aug. 31, 2015 $ / shares shares	Jun. 12, 2014 $ / shares shares	Sep. 30, 2016 USD ($) shares	Sep. 30, 2015	Sep. 30, 2016 USD ($) Plan $ / shares shares	Sep. 30, 2015	Dec. 31, 2015 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stockholders equity reverse stock split ratio	0.33
Number of equity incentive plans \| Plan										2
Total Shares Outstanding								926,608		926,608		713,659
Number of Shares, Granted										276,628
Unrecognized stock-based compensation expense, weighted-average recognition period										2 years 1 month 6 days
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding \| $								$ 0		$ 0
Intrinsic value of options vested and unvested expected to vest \| $								0		0
Intrinsic value of options exercisable \| $								0		$ 0
Option awards assumptions, method used										Black-Scholes pricing model
Weighted-average estimated fair value of options granted \| $ / shares										$ 1.86
Percentage of Overall Stock Grant Subject to Vesting										100.00%
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted \| $ / shares							$ 16.05
Percentage of Overall Stock Grant Subject to Vesting										100.00%
Vesting period										1 year
Intrinsic value shares, RSUs outstanding \| $								277,496		$ 277,496
Intrinsic value amount, RSUs unvested and vested expected to vest \| $								270,904		$ 270,904
Issuance of restricted stock units							14,832			165,829
Total RSUs forfeited										10,383
RSUs [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of vested shares issued										4,449
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense, stock options \| $								$ 2,081,000		$ 2,081,000
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stockholders equity reverse stock split ratio	0.33
2013 Equity Incentive Plan [Member] \| Stock Options [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average estimated fair value of options granted \| $ / shares					$ 2.87	$ 4.40
Number of Shares, Granted					33,333	33,333
2013 Equity Incentive Plan [Member] \| RSUs [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting			100.00%
Vesting period			1 year
Restricted stock units, grant date fair value \| $ / shares			$ 1.95
Restricted stock unit award, shares			25,000
2013 Equity Incentive Plan [Member] \| Retention RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				1 year
Restricted stock units, grant date fair value \| $ / shares				$ 1.86
Restricted stock units, grant date fair value \| $				$ 108,498
2013 Equity Incentive Plan [Member] \| Retention RSUs [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units				25,000
2013 Equity Incentive Plan [Member] \| Retention RSUs [Member] \| Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of restricted stock units				58,332
2013 Equity Incentive Plan [Member] \| Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized								1,022,955		1,022,955
Stock options and RSUs issued										978,358
Total Shares Outstanding								978,358		978,358
Common stock, shares authorized								3,115		3,115
2013 Equity Incentive Plan [Member] \| Inducement shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized								333,333		333,333
Stock options and RSUs issued										124,999
Total Shares Outstanding								124,999		124,999
Common stock, shares authorized								208,334		208,334
2013 Equity Incentive Plan [Member] \| Options Vesting on One Year Anniversary [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			66,666
Weighted-average estimated fair value of options granted \| $ / shares			$ 1.45
Percentage of Overall Stock Grant Subject to Vesting			25.00%
Vesting period			1 year
Stock option units remaining vesting period on Equal monthly basis			3 years
2013 Equity Incentive Plan [Member] \| Options Vesting on Performance Achievement [Member] \| Chief Financial Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized		33,333
Weighted-average estimated fair value of options granted \| $ / shares		$ 1.26
2013 Equity Incentive Plan [Member] \| Pre-reverse Stock Split [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			1,000,000
2013 Equity Incentive Plan [Member] \| Post-reverse Stock Split [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			333,333
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate								8.00%	4.00%	8.00%	4.00%
Maximum [Member] \| 2013 Equity Incentive Plan [Member] \| Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized	3,068,865
Maximum [Member] \| 2013 Equity Incentive Plan [Member] \| Inducement shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized	1,000,000
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate								0.00%	0.00%	0.00%	0.00%
Minimum [Member] \| 2013 Equity Incentive Plan [Member] \| Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized	1,022,955
Minimum [Member] \| 2013 Equity Incentive Plan [Member] \| Inducement shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized	333,333

XML 49 R38.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Vested and unvested expected to vest, Beginning Balance	646,900
Number of Shares Outstanding, Beginning Balance	713,659
Number of Shares, Granted	276,628
Number of Shares, Cancelled/forfeited/expired	(63,679)
Number of Shares Outstanding, Ending Balance	926,608	713,659
Number of Shares, Vested and unvested expected to vest, Ending Balance	838,037	646,900
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Beginning Balance	$ 15.48
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	11.23
Weighted Average Exercise Price Per Share, Granted	2.60
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	8.08
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	8.87	$ 11.23
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 9.37	$ 15.48
Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 1 month 6 days	9 years
Average Remaining Contractual Term in Years, Outstanding	8 years 8 months 12 days	9 years

XML 50 R39.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	9 Months Ended
	Sep. 30, 2016 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 1.57
Discount rate-bond equivalent yield	0.99%
Expected life (in years)	5 years 1 month 17 days
Expected volatility	80.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 4.02
Discount rate-bond equivalent yield	1.39%
Expected life (in years)	6 years 29 days
Expected volatility	90.00%

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail)	9 Months Ended
	Sep. 30, 2016
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
Stock Options [Member] \| Minimum Number of Accessions Processed, Billed and Collected [Member] \| 2013 Equity Incentive Plan [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	13.00%
Stock Options [Member] \| Minimum Revenues from Contracts with Pharmaceutical Companies [Member] \| 2013 Equity Incentive Plan [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	10.00%
Stock Options [Member] \| Attainment of a Sustainable Positive GAAP Gross Margin [Member] \| 2013 Equity Incentive Plan [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	12.00%
Stock Options [Member] \| Minimum Operating Cash on-Hand with no More than One Interim Dilutive Equity Financing Event [Member] \| 2013 Equity Incentive Plan [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
Stock Options [Member] \| Achievement of the Company's 2016 Corporate Goals [Member] \| 2013 Equity Incentive Plan [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
Stock Options [Member] \| Completion of a Board-approved Strategic Transaction [Member] \| 2013 Equity Incentive Plan [Member] \| Chief Executive Officer [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	100.00%
RSUs [Member] \| Minimum Revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	25.00%
RSUs [Member] \| Maximum EBITDA Loss [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	15.00%
RSUs [Member] \| Attainment of Financial Plan for Fiscal 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] \| Minimum Value of Strategic Agreements [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%
RSUs [Member] \| Implementation of Four New Diagnostic Test Panels [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall Stock Grant Subject to Vesting	20.00%

XML 52 R41.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of RSU Activity for Awards Granted (Detail) - RSUs [Member] - $ / shares		9 Months Ended
	Jun. 12, 2014	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Vested and unvested expected to vest, Beginning Balance		15,369
Number of Shares Outstanding, Beginning Balance		25,752
Number of Shares, Granted	14,832	165,829
Number of share, Vested and issued		(4,449)
Number of share, Forfeited		(10,383)
Number of Shares Outstanding, Ending Balance		176,749
Number of Shares, Vested and unvested expected to vest, Ending Balance		172,550
Weighted Average Grand Date Fair Value, Vested unvested expected to vest, Beginning Balance		$ 14.49
Weighted Average Grand Date Fair Value, Outstanding, Beginning Balance		15.12
Weighted Average Grand Date Fair Value, Granted		1.96
Weighted Average Grand Date Fair Value, Vested and issued		16.05
Weighted Average Grand Date Fair Value, Forfeited		16.05
Weighted Average Grand Date Fair Value, Outstanding, Ending Balance		2.70
Weighted Average Grand Date Fair Value, Vested unvested expected to vest, Ending Balance		$ 2.71

XML 53 R42.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 406,613	$ 325,231	$ 1,097,439	$ 914,689
Stock Options [Member] \| Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	34,119	15,029	89,606	48,839
Stock Options [Member] \| Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	28,189	20,910	87,153	65,835
Stock Options [Member] \| General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	292,381	257,404	829,516	706,026
Stock Options [Member] \| Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	51,924	31,888	91,164	93,989
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	465,269	339,371	1,164,979	1,016,266
RSUs [Member] \| Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	14,918		16,834
RSUs [Member] \| Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	14,131	1,625	15,583	10,724
RSUs [Member] \| General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	6,668	$ 12,515	7,676	$ 90,853
RSUs [Member] \| Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 22,939		$ 27,447

XML 54 R43.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding - Additional Information (Detail)	Sep. 27, 2016	Sep. 30, 2016 USD ($)
Warrants And Rights Note Disclosure [Abstract]
Reverse stock split of common shares outstanding	0.33
Common stock warrants exercisable, intrinsic value		$ 0
Common stock warrants outstanding, intrinsic value		$ 0

XML 55 R44.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	784,234
Number of Shares, Issued	1,163,526
Number of Shares, Expired	(50,904)
Number of Shares, Outstanding, Ending Balance	1,896,856	784,234
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 11.19
Weighted Average Exercise Price Per Share, Issued	3.90
Weighted Average Exercise Price Per Share, Expired	30.00
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 6.21	$ 11.19
Average Remaining Contractual Term (in years)	4 years 1 month 6 days	3 years 9 months 18 days

XML 56 R45.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Additional Information (Detail)	Sep. 27, 2016
Earnings Per Share [Abstract]
Reverse stock split of common shares outstanding	0.33

XML 57 R46.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	3,000,742	1,533,023	3,000,742	1,533,023
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	1,896,856	797,579	1,896,856	797,579
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	529	529	529	529
Preferred Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		24,384		24,384
Common Share RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	176,749	25,752	176,749	25,752
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	926,608	684,779	926,608	684,779

XML 58 R47.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 29, 2016	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Unconditional purchase commitment aggregate amount	$ 1,062,500
Unconditional purchase commitment, quarterly payment amount	$ 62,500
Unconditional purchase commitment payment terms		Quarterly
Unconditional purchase commitment period		May 31, 2020

XML 59 R48.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail)			3 Months Ended		9 Months Ended
	May 04, 2016 USD ($) Director shares	Feb. 09, 2015 USD ($) shares	Sep. 30, 2016 USD ($) ft²	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) ft²	Sep. 30, 2015 USD ($)	Feb. 13, 2015 shares
Related Party Transaction [Line Items]
Issuance of warrants to purchase shares of common stock \| shares	1,163,526						400,000
Rental income			$ 38,412	$ 38,412	$ 115,236	$ 64,020
Director [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued \| shares	58,335	47,331
Issuance of warrants to purchase shares of common stock \| shares	40,832	47,331
Proceeds from issuance of common stock	$ 175,000	$ 177,500
Number of members of board of directors \| Director	3
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs					$ 19,047
Nonexecutive [Member]
Related Party Transaction [Line Items]
Lease agreement date of commencement					Mar. 30, 2015
Leased facility, rent expense per month					$ 12,804
Lease facility, refundable security deposit amount			$ 12,804		$ 12,804
Lease expiration date					Jul. 31, 2015
Nonexecutive [Member] \| San Diego California Facility [Member]
Related Party Transaction [Line Items]
Leased facility, expansion of original premises \| ft²			9,849		9,849
Major Stockholder, Claire K.T. Reiss [Member]
Related Party Transaction [Line Items]
Initial public offering, number of shares issued \| shares	204,758
Issuance of warrants to purchase shares of common stock \| shares	143,330
Proceeds from issuance of common stock	$ 614,273

XML 60 R49.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail)							1 Months Ended	9 Months Ended
Subsequent Events - Additional Information (Detail)	Oct. 19, 2016 USD ($) $ / shares shares	Oct. 14, 2016 USD ($) Director Consultant $ / shares shares	May 04, 2016 USD ($) Director $ / shares shares	Dec. 21, 2015 USD ($) $ / shares shares	Feb. 13, 2015 USD ($) $ / shares shares	Feb. 09, 2015 USD ($) shares	Nov. 09, 2016 USD ($)	Sep. 30, 2016 USD ($) $ / shares	Sep. 30, 2015 USD ($)	Dec. 31, 2015 $ / shares
Subsequent Event [Line Items]
Issuance of warrants to purchase shares of common stock \| shares			1,163,526		400,000
Stock price \| $ / shares								$ 2.70
Purchase of common stock by underwriters to cover overallotments, grant date fair value			$ 2,000,000					$ 7,700,000
Overallotment issued to underwriter to purchase common stock, period						45 days		45 days
Purchase of common stock by underwriters to cover overallotments, number of shares \| shares					400,000
Purchase of common stock by underwriters to cover overallotments, per share \| $ / shares					$ 3.75			$ 3.75
Common stock, par value \| $ / shares					$ 0.0003			$ 0.0001		$ 0.0001
Proceeds from exercise of common stock warrants					$ 9,800,000				$ 9,697,660
Issuance of warrants to purchase shares of common stock, grant date fair value					$ 1,600,000			$ 1,600,000
Exercise price of warrants \| $ / shares			$ 3.90		$ 4.68
Underwriters discount and additional costs paid					$ 900,000
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs					9,100,000
Underwriter cost					200,000
Non-underwriter costs					$ 300,000
Increase in capital shares value						$ 8,800,000		$ 1,400,000
Common Stock [Member] \| Aspire Capital Fund, LLC [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued \| shares				208,334
Stock price \| $ / shares				$ 4.80
Proceeds from issuance of common stock				$ 1,000,000
Overallotment issued to underwriter to purchase common stock, period				30 months
Increase in capital shares value				$ 15,000,000
Common stock purchase agreement termination date								Nov. 04, 2016
Director [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued \| shares			58,335			47,331
Issuance of warrants to purchase shares of common stock \| shares			40,832			47,331
Proceeds from issuance of common stock			$ 175,000			$ 177,500
Number of members of board of directors \| Director			3
Major Stockholder, Claire K.T. Reiss [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued \| shares			204,758
Issuance of warrants to purchase shares of common stock \| shares			143,330
Proceeds from issuance of common stock			$ 614,273
Subsequent Event [Member]
Subsequent Event [Line Items]
Estimated grant date fair value of warrants \| $ / shares	$ 0.57	$ 0.57
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 5,200,000	$ 5,200,000
Overallotment issued to underwriter to purchase common stock, period	30 days	30 days
Purchase of common stock by underwriters to cover overallotments, number of shares \| shares	627,131	627,131
Purchase of common stock by underwriters to cover overallotments, per share \| $ / shares	$ 1.0331	$ 1.0331
Common stock, par value \| $ / shares	$ 0.0009	$ 0.0009
Proceeds from exercise of common stock warrants	$ 564	$ 564					$ 0
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 800,000	$ 800,000
Exercise price of warrants \| $ / shares	$ 1.10	$ 1.10
Class of warrant or rights, term	5 years	5 years
Number of consultants \| Consultant		1
Underwriters discount and additional costs paid	$ 600,000
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs	9,400,000
Increase in capital shares value	8,800,000
Underwriter cost	$ 600,000
Non-underwriter costs		$ 600,000
Subsequent Event [Member] \| Director [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued \| shares		534,088
Issuance of warrants to purchase shares of common stock \| shares		534,088
Proceeds from issuance of common stock		$ 587,497
Number of members of board of directors \| Director		3
Subsequent Event [Member] \| Director [Member] \| Chief Executive Officer [Member]
Subsequent Event [Line Items]
Number of members of board of directors \| Director		7
Subsequent Event [Member] \| Major Stockholder, Claire K.T. Reiss [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued \| shares		227,272
Issuance of warrants to purchase shares of common stock \| shares		227,272
Proceeds from issuance of common stock		$ 249,999
Subsequent Event [Member] \| Consultants [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued \| shares		79,090
Issuance of warrants to purchase shares of common stock \| shares		79,090
Proceeds from issuance of common stock		$ 86,999
Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Issuance of warrants to purchase shares of common stock \| shares	1,365,000	1,365,000
Purchase of common stock by underwriters to cover overallotments, number of shares \| shares	1,365,000	1,365,000
Subsequent Event [Member] \| Roth Capital Partners, LLC and Feltl [Member]
Subsequent Event [Line Items]
Public offering, number of shares issued \| shares		9,100,000
Issuance of warrants to purchase shares of common stock \| shares	9,100,000	9,100,000
Stock price \| $ / shares		$ 1.10
Proceeds from issuance of common stock		$ 10,000,000

XML 61 R50.htm IDEA: XBRL DOCUMENT

Subsequent Events - Assumptions Used for Determining Fair Values of Overallotment Options, Overallotment Warrants and Non-overallotment Warrants Issued (Detail) - $ / shares		9 Months Ended
	Oct. 14, 2016	Sep. 30, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price		$ 2.70
Exercise price		$ 3.90
Expected dividend yield		0.00%
Discount rate-bond equivalent yield		1.23%
Expected life (in years)		5 years
Expected volatility		90.00%
Subsequent Event [Member] \| Overallotment Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 0.93
Exercise price	$ 1.0331
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	0.25%
Expected life (in years)	29 days
Expected volatility	12.90%
Subsequent Event [Member] \| Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 0.93
Exercise price	$ 1.10
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.24%
Expected life (in years)	5 years
Expected volatility	80.00%

EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 200 291 1 false 64 0 false 8 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biocept.com/20160930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Balance Sheets Sheet http://www.biocept.com/20160930/taxonomy/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.biocept.com/20160930/taxonomy/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.biocept.com/20160930/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.biocept.com/20160930/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://www.biocept.com/20160930/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnauditedParenthetical Condensed Statements of Cash Flows (Unaudited) (Parenthetical) Statements 6 false false R7.htm 100060 - Disclosure - Basis of Presentation Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureBasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 100070 - Disclosure - Liquidity and Going Concern Uncertainty Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertainty Liquidity and Going Concern Uncertainty Notes 8 false false R9.htm 100080 - Disclosure - Sales of Equity Securities Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureSalesOfEquitySecurities Sales of Equity Securities Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurement Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureFairValueMeasurement Fair Value Measurement Notes 10 false false R11.htm 100100 - Disclosure - Balance Sheet Details Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 11 false false R12.htm 100110 - Disclosure - April 2014 Credit Facility Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureApril2014CreditFacility April 2014 Credit Facility Notes 12 false false R13.htm 100120 - Disclosure - Capital Lease Obligations Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCapitalLeaseObligations Capital Lease Obligations Notes 13 false false R14.htm 100130 - Disclosure - Stock-based Compensation Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensation Stock-based Compensation Notes 14 false false R15.htm 100140 - Disclosure - Common Stock Warrants Outstanding Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCommonStockWarrantsOutstanding Common Stock Warrants Outstanding Notes 15 false false R16.htm 100150 - Disclosure - Net Loss per Common Share Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShare Net Loss per Common Share Notes 16 false false R17.htm 100160 - Disclosure - Commitments and Contingencies Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 100170 - Disclosure - Related Party Transactions Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 18 false false R19.htm 100180 - Disclosure - Subsequent Events Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 100190 - Disclosure - Basis of Presentation (Policies) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureBasisOfPresentationPolicies Basis of Presentation (Policies) Policies 20 false false R21.htm 100200 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureFairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.biocept.com/20160930/taxonomy/role/DisclosureFairValueMeasurement 21 false false R22.htm 100210 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.biocept.com/20160930/taxonomy/role/DisclosureBalanceSheetDetails 22 false false R23.htm 100220 - Disclosure - Capital Lease Obligations (Tables) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCapitalLeaseObligationsTables Capital Lease Obligations (Tables) Tables http://www.biocept.com/20160930/taxonomy/role/DisclosureCapitalLeaseObligations 23 false false R24.htm 100230 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensation 24 false false R25.htm 100240 - Disclosure - Common Stock Warrants Outstanding (Tables) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCommonStockWarrantsOutstandingTables Common Stock Warrants Outstanding (Tables) Tables http://www.biocept.com/20160930/taxonomy/role/DisclosureCommonStockWarrantsOutstanding 25 false false R26.htm 100250 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://www.biocept.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShare 26 false false R27.htm 100260 - Disclosure - Subsequent Events (Tables) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureSubsequentEventsTables Subsequent Events (Tables) Tables http://www.biocept.com/20160930/taxonomy/role/DisclosureSubsequentEvents 27 false false R28.htm 100270 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformationDetail Basis of Presentation - Additional Information (Detail) Details 28 false false R29.htm 100280 - Disclosure - Liquidity and Going Concern Uncertainty- Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertaintyAdditionalInformationDetail Liquidity and Going Concern Uncertainty- Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Sales of Equity Securities - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureSalesOfEquitySecuritiesAdditionalInformationDetail Sales of Equity Securities - Additional Information (Detail) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureFairValueMeasurementOtherFairValueMeasurementsAdditionalInformationDetail Fair Value Measurement - Other Fair Value Measurements - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureFairValueMeasurementAssumptionsUsedForDeterminingFairValuesOfCommonStockWarrantsDetail Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Details 32 false false R33.htm 100320 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfFixedAssetsAndAccruedLiabilitiesDetail Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) Details 33 false false R34.htm 100330 - Disclosure - April 2014 Credit Facility - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureApril2014CreditFacilityAdditionalInformationDetail April 2014 Credit Facility - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Capital Lease Obligations - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCapitalLeaseObligationsAdditionalInformationDetail Capital Lease Obligations - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Capital Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Lease Obligations (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCapitalLeaseObligationsScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseObligationsDetail Capital Lease Obligations - Schedule of Future Minimum Lease Payments for Capital Lease Obligations (Detail) Details 36 false false R37.htm 100360 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-based Compensation - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityForOptionAwardsGrantedDetail Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) Details 38 false false R39.htm 100380 - Disclosure - Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForDeterminingFairValueOfStockOptionsUnderBlackScholesPricingModelDetail Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) Details 39 false false R40.htm 100390 - Disclosure - Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfPerformanceStockUnitsVestingPercentageDetail Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail) Details 40 false false R41.htm 100400 - Disclosure - Stock-based Compensation - Summary of RSU Activity for Awards Granted (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityForAwardsGrantedDetail Stock-based Compensation - Summary of RSU Activity for Awards Granted (Detail) Details 41 false false R42.htm 100410 - Disclosure - Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureStockBasedCompensationEffectsOfStockBasedCompensationRelatedToEquityAwardsToEmployeesAndNonemployeesOnCondensedStatementOfOperationsAndComprehensiveLossDetail Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) Details 42 false false R43.htm 100420 - Disclosure - Common Stock Warrants Outstanding - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCommonStockWarrantsOutstandingAdditionalInformationDetail Common Stock Warrants Outstanding - Additional Information (Detail) Details 43 false false R44.htm 100430 - Disclosure - Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCommonStockWarrantsOutstandingSummaryOfEquityClassifiedCommonStockWarrantActivityDetail Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) Details 44 false false R45.htm 100440 - Disclosure - Net Loss per Common Share - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail Net Loss per Common Share - Additional Information (Detail) Details 45 false false R46.htm 100450 - Disclosure - Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesDetail Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) Details 46 false false R47.htm 100460 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 47 false false R48.htm 100470 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 48 false false R49.htm 100480 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 49 false false R50.htm 100490 - Disclosure - Subsequent Events - Assumptions Used for Determining Fair Values of Overallotment Options, Overallotment Warrants and Non-overallotment Warrants Issued (Detail) Sheet http://www.biocept.com/20160930/taxonomy/role/DisclosureSubsequentEventsAssumptionsUsedForDeterminingFairValuesOfOverallotmentOptionsOverallotmentWarrantsAndNonOverallotmentWarrantsIssuedDetail Subsequent Events - Assumptions Used for Determining Fair Values of Overallotment Options, Overallotment Warrants and Non-overallotment Warrants Issued (Detail) Details 50 false false All Reports Book All Reports bioc-20160930.xml bioc-20160930.xsd bioc-20160930_cal.xml bioc-20160930_def.xml bioc-20160930_lab.xml bioc-20160930_pre.xml true true ZIP 68 0001564590-16-028909-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-028909-xbrl.zip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�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end

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☒

		Page

IMPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS		3

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements	4

	Condensed Balance Sheets as of December 31, 2015 and September 30, 2016 (unaudited)	4

	Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2015 and 2016 (unaudited)	5

	Condensed Statements of Cash Flows for the nine months ended September 30, 2015 and 2016 (unaudited)	6

	Notes to Condensed Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	28

Item 4.	Controls and Procedures	28

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	29

Item 1A.	Risk Factors	29

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31

Item 3.	Defaults Upon Senior Securities	31

Item 4.	Mine Safety Disclosures	31

Item 5.	Other Information	31

Item 6.	Exhibits	31

	Nine Months Ended September 30,				Change
	2015		2016		#		%
Commercial cases accessioned		1,024		2,727		1,703		166	%

Exhibit No.		Description of Exhibit

3.1		Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1.4 of the Registrant’s Current Report on Form 8-K, filed with the SEC on February 14, 2014).
3.2		Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
3.3		Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 29, 2016).
4.1		Reference is made to Exhibits 3.1 and 3.2.
4.2		Specimen Common Stock certificate of Biocept, Inc. (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), as amended, filed with the SEC on November 5, 2013).
4.3		Form of Representative’s Warrant, dated February 10, 2014 (incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), as amended, filed with the SEC on November 20, 2013).
4.4		Form of Warrant issued to the lender under the Loan and Security Agreement, dated as of April 30, 2014, by and among Biocept, Inc., Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time, including Oxford Finance LLC (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on May 6, 2014).
4.5		Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.5 of the Registrant’s Registration Statement on Form S-1 (File No. 333-201437), filed with the SEC on February 6, 2015).
4.6		Warrant to Purchase Preferred Stock, dated September 10, 2012, issued by the Registrant in favor of ARE-SD Region No. 18, LLC (incorporated by reference to Exhibit 10.11.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.7		Warrant to Purchase Common Stock, dated September 10, 2013, issued by the Registrant in favor of ARE-SD Region No. 18, LLC (incorporated by reference to Exhibit 10.11.6 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.8		Warrant to Purchase Preferred Stock dated as of January 21, 2009, issued by the Registrant in favor of Goodman Co. Ltd. (incorporated by reference to Exhibit 10.17.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.9		Warrant to Purchase Common Stock dated as of July 31, 2013, issued by the Registrant in favor of Goodman Co. Ltd. (incorporated by reference to Exhibit 10.17.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.10		Form of Warrant to Purchase Preferred Stock, issued by the Registrant in favor of various investors under the Note and Warrant Purchase Agreement dated as of January 13, 2012 (incorporated by reference to Exhibit 10.19.3 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.11		Form of Amendment of Warrant to Purchase Preferred Stock, dated as of September 13, 2013 (incorporated by reference to Exhibit 10.19.4 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.12		Form of Warrant to Purchase Common Stock, issued by the Registrant in favor of various investors under the Note and Warrant Purchase Agreement dated as of June 28, 2013 (incorporated by reference to Exhibit 10.20.2 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.13		Form of Warrant to Purchase Common Stock, issued by the Registrant in favor of various guarantors under the Reimbursement Agreement dated as of July 11, 2013 (incorporated by reference to Exhibit 10.21.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.14		Amended and Restated Investor Rights Agreement, dated as of October 31, 2011, among the Registrant and certain investors named therein (incorporated by reference to Exhibit 10.12 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
4.15		Form of Common Stock Purchase Warrant issued to the investors under the Securities Purchase Agreement, dated April 29, 2016, by and among Biocept, Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on April 29, 2016).
4.16		Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.16 of the Registrant’s Post-Effective Amendment to Registration Statement on Form S-1 (File No. 333-213111), filed with the SEC on October 14, 2016).
10.1+		Employment Agreement between the Registrant and Timothy Kennedy, dated July 25, 2016 (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K (File No. 001-36284), filed with the SEC on July 27, 2016).

	For the three months ended September 30,						For the nine months ended September 30,
	2015			2016			2015			2016
Revenues:	$	164,856		$	1,047,280		$	391,626		$	1,931,509
Costs and expenses:
Cost of revenues		1,159,710			1,876,288			3,320,467			5,020,649
Research and development expenses		677,729			600,613			2,073,391			2,044,968
General and administrative expenses		1,630,608			1,919,843			4,281,883			4,924,731
Sales and marketing expenses		1,055,653			1,278,455			2,616,218			3,875,063
Total costs and expenses		4,523,700			5,675,199			12,291,959			15,865,411
Loss from operations		(4,358,844	)		(4,627,919	)		(11,900,333	)		(13,933,902	)
Other income/(expense):
Interest expense, net		(175,562	)		(154,869	)		(494,235	)		(393,029	)
Other income		38,412			38,412			64,020			115,236
Gain on sale of fixed assets		—			1,300			—			1,300
Total other income/(expense):		(137,150	)		(115,157	)		(430,215	)		(276,493	)
Loss before income taxes		(4,495,994	)		(4,743,076	)		(12,330,548	)		(14,210,395	)
Income tax expense		(199	)		—			(1,478	)		(2,053	)
Net loss and comprehensive loss	$	(4,496,193	)	$	(4,743,076	)	$	(12,332,026	)	$	(14,212,448	)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic		6,242,604			8,370,691			5,245,303			7,549,663
Diluted		6,242,604			8,370,691			5,245,303			7,549,663
Net loss per common share:
Basic	$	(0.72	)	$	(0.57	)	$	(2.35	)	$	(1.88	)
Diluted	$	(0.72	)	$	(0.57	)	$	(2.35	)	$	(1.88	)

	Three Months Ended September 30,				Change
	2015		2016		#		%
Commercial cases accessioned		443		1,023		580		131	%

	Nine Months Ended
	September 30,
	2015			2016
(dollars in thousands)
Cash provided by (used in):
Operating activities	$	(10,896	)	$	(11,257	)
Investing activities		(119	)		(391	)
Financing activities		18,192			3,506
Net increase (decrease) in cash and cash equivalents	$	7,177		$	(8,142	)

	BIOCEPT, INC. (Registrant)

Date: November 10, 2016	By:	/s/ Michael W. Nall
		Michael W. Nall
		President, Chief Executive Officer and Director
		(Principal Executive Officer)

Date: November 10, 2016	By:	/s/ Timothy C. Kennedy
		Timothy C. Kennedy
		Chief Financial Officer, Senior Vice President of Operations
		(Principal Financial and Accounting Officer)